<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3-5251-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        XOROLA 2.5MG F.C.TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LETROZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        115.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Sindan pharma SRL " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Sindan pharma SRL 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L02BG04 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Xorola contains an active substance called letrozole. It belongs to a group of medicines called&nbsp;aromatase inhibitors. It is a hormonal (or &ldquo;endocrine&rdquo;) breast cancer treatment.&nbsp;Growth of breast cancer is frequently stimulated by oestrogens which are female sex hormones. Xorola reduces the amount of oestrogen by blocking an enzyme&nbsp;(&ldquo;aromatase&rdquo;)&nbsp;involved in the production of oestrogens and therefore may block the growth of breast cancer that needs oestrogens to grow. As a consequence tumour cells slow or stop growing and/or spreading to other parts of the body.</p><p><strong>What Xorola is used for</strong></p><p>Xorola is used to treat breast cancer in women who have gone through menopause i.e cessation of periods.</p><p>It is used to prevent cancer from happening again. It can be used as first treatment before breast cancer surgery in case immediate surgery is not suitable or it can be used as first treatment after breast cancer surgery or following five years treatment with tamixofen. Xorola is also used to prevent breast tumour spreading to other parts of the body in patients with advanced breast cancer.</p><p>If you have any questions about how Xorola works or why this medicine has been prescribed for you, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow all the doctor&rsquo;s instructions carefully. They may differ from the general information in this leaflet</p><p><strong>Do not take Xorola</strong></p><ul><li>if you are allergic to letrozole or any of the other ingredients of this medicine (listed in section 6),</li><li>if you still have periods, i.e. if you have not yet gone through the menopause,</li><li>if you are pregnant,</li><li>- if you are breastfeeding</li></ul><p>If any of these conditions apply to you,&nbsp;<strong>do not take this medicine and talk to your doctor.</strong></p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Xorola</p><ul><li>- if you have a severe kidney disease</li><li>- if you have severe liver disease</li><li>- if you have a history of osteoporosis or bone fractures (see also&nbsp;&ldquo;Follow-up during Xorola&nbsp;treatment&rdquo;&nbsp;in section 3).</li></ul><p>If any of these conditions apply to you,&nbsp;tell your doctor. Your doctor will take this into account during your treatment with Xorola.</p><p>&nbsp;</p><p><strong>Children and adolescents (below 18 years)</strong></p><p>Children and adolescents should not use this medicine.</p><p>&nbsp;</p><p><strong>Older people (age 65 years and over)</strong></p><p>People aged 65 years and over can use this medicine at the same dose as for other adults.</p><p>&nbsp;</p><p><strong>Other medicines and Xorola</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><ul><li><p>- &nbsp;You should only take Xorola when you have gone through the menopause. However, your doctor should discuss with you about using effective contraceptive, as you may still have the potential to become pregnant during treatment with Xorola.</p></li><li><p>- &nbsp;You must not take Xorola if you are pregnant or breast feeding as it may harm your baby.</p></li></ul><p>&nbsp;</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>If you feel dizzy, tired, drowsy or generally unwell, do not drive or operate any tools or machines until you feel normal again.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Xorola contains lactose</strong></p><p>Xorola contains lactose (milk sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose is one tablet of Xorola to be taken once a day. Taking Xorola at the same time each day will help you remember when to take your tablet.</p><p>The tablet can be taken with or without food and should be swallowed whole with a glass of water or another liquid.</p><p>How long to take Xorola<br />Continue taking Xorola every day for as long as your doctor tells you. You may need to take it for months or even years. If you have any questions about how long to keep taking Xorola, talk to your doctor.</p><p><u>Follow-up during Xorola treatment</u><br />You should only take this medicine under strict medical supervision. Your doctor will regularly monitor your condition to check whether the treatment is having the right effect.</p><p>Xorola may cause thinning or wasting of your bones (osteoporosis) due to the reduction of oestrogens in your body. Your doctor may decide to measure your bone density (a way of monitoring for osteoporosis) before, during and after treatment.</p><p><strong>If you take more Xorola than you should</strong></p><p>If you have taken too much Xorola, or if someone else accidentally takes your tablets, contact a doctor or hospital for advice immediately. Show them the pack of tablets. Medical treatment may be necessary.</p><p>If you forget to take Xorola</p><ul><li><p>- &nbsp;If it is almost time for the next dose (e.g. within 2 or 3 hours), skip the dose you missed and take your next dose when you are meant to.</p></li><li><p>- &nbsp;Otherwise, take the dose as soon as you remember, and then take the next tablet as you would normally.</p></li><li><p>- &nbsp;Do not take a double dose to make up for a forgotten dose.</p></li></ul><p>&nbsp;</p><p><strong>If you stop taking Xorola</strong></p><p>Do not stop taking Xorola&nbsp;unless your doctor tells you to. See also the section above &ldquo;How long to&nbsp;take Xorola&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Most of the side effects are mild to moderate and will generally disappear after a few days to a few weeks of treatment.</p><p>Some of these side effects, such as hot flushes, hair loss or vaginal bleeding, may be due to the lack of oestrogens in your body.</p><p>Do not be alarmed by this list of possible side effects. You may not experience any of them.</p><p><strong>Some side effects could be serious:</strong><br />Rare or uncommon side effects&nbsp;(i.e. they may affect between 1 to 100 in every 10,000 patients):</p><ul><li><p>- &nbsp;Weakness, paralysis or loss of feeling in any part of the body (particularly arm or leg),&nbsp;loss of coordination, nausea, or difficulty speaking or breathing (sign of a brain&nbsp;disorder,e.g. stroke)</p></li><li><p>- &nbsp;Sudden oppressive chest pain (sign of a heart disorder).</p></li><li><p>- &nbsp;Difficulty breathing, chest pain, fainting, rapid heart rate, bluish skin discoloration, or sudden&nbsp;arm, leg or foot pain (signs that a blood clot may have formed).</p></li><li><p>- &nbsp;Swelling and redness along a vein which is extremely tender and possibly painful when touched.</p></li><li><p>- &nbsp;Severe fever, chills or mouth ulcers due to infections (lack of white blood cells).</p></li><li><p>- &nbsp;Severe persistent blurred vision.</p></li></ul><p><strong>If any of the above occurs, tell your doctor straight away.</strong></p><p>&nbsp;</p><p>You should also inform the doctor straight away if you experience any of the following symptoms during treatment with Xorola:</p><ul><li><p>- &nbsp;Swelling mainly of the face and throat (signs of allergic reaction).</p></li><li><p>- &nbsp;Yellow skin and eyes, nausea, loss of appetite, dark-coloured urine (signs of hepatitis).</p></li><li>- &nbsp;Rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (signs of skin disorder).</li></ul><p>&nbsp;</p><p>Other side effects</p><p><strong>Very common (may affect more than 1 in 10 people)</strong></p><ul><li><p>- &nbsp;Hot flushes</p></li><li><p>- &nbsp;Increased level of cholesterol (hypercholesterolaemia)</p></li><li><p>- &nbsp;Fatigue</p></li><li><p>- &nbsp;Increased sweating</p></li><li><p>- &nbsp;Pain in bones and joints (arthralgia)</p></li></ul><p><br />If any of these affects you severely, tell your doctor.</p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><ul><li>Skin rash</li><li>Headache</li><li>Dizziness</li><li>Malaise (generally feeling unwell)</li><li>Gastrointestinal disorders such as nausea, vomiting, indigestion, constipation, diarrhoea Increase in or loss of appetite</li><li>Pain in muscles</li><li>Thinning or wasting of your bones (osteoporosis), leading to bone fractures in some cases (see also&nbsp;&ldquo;Follow-up during Xorola treatment&rdquo;&nbsp;in section 3)</li><li>Swelling of arms, hands, feet, ankles (oedema)</li><li>Depression</li><li>Weight increase</li><li>Hair loss</li><li>Raised blood pressure (hypertension)</li><li>Abdominal pain</li><li>Dry skin</li><li>Vaginal bleeding</li></ul><p>If any of these affects you severely, tell your doctor.</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><ul><li>Nervous disorders such as anxiety, nervousness, irritability, drowsiness, memory problems, somnolence, insomnia</li><li>Impairment of sensation, especially that of touch</li><li>Eye disorders such as blurred vision, eye irritation</li><li>Palpitations, rapid heart rate</li><li>Skin disorders such as itching (urticaria)</li><li>Vaginal discharge or dryness</li><li>Joint stiffness (arthritis)</li><li>Breast pain</li><li>Fever</li><li>Thirst, taste disorder, dry mouth</li><li>Dryness of mucous membranes</li><li>Weight decrease</li><li>Urinary tract infection, increased frequency of urination Cough</li><li>Increased level of enzymes</li></ul><p>If any of these affects you severely, tell your doctor.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the National Pharmacovigilance and Drug Safety Centre (NPC) +966-11-2038222. Exts: 2317-2356-2353-2354-2334-2340. Toll free phone: 8002490000. E-mail: npc.drug@sfda.gov.sa. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>This medicinal product does not require any special storage conditions.</p><p>Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use . These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- -</p><p>The active substance is letrozole. Each film-coated tablet contains 2.5 mg letrozole. The other ingredients are:<br />Tablet core:&nbsp;lactose monohydrate, maize starch, sodium starch glycolate type A, microcrystalline cellulose, colloidal anhydrous silica, magnesium stearate.</p><p>Tablet coating:&nbsp;polyvinyl alcohol, talc, macrogol 3350, titanium dioxide (E171) and iron oxide yellow (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Xorola 2.5 mg are yellow, round, lenticular film-coated tablets.
Pack sizes:
Blisters: 10, 14, 20, 28, 30, 50, 60, 84, 100 and 120 film-coated tablets
Tablet containers closed with child resistant screw cap: 30, 100 film-coated tablets
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Actavis Group PTC ehf.</p><p>Reykjavikurvegur 76 - 78</p><p>220 Hafnarfjördur</p><p>Iceland</p><p><strong>Manufacturer</strong><br />Tadawi Biomedical company&nbsp;<br />Olaya st,<br />Riyadh<br />Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                06/2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي&nbsp;<strong>زورولا</strong>&nbsp;على المادة الفعالة المسماة ليتروزول. وهي تنتمي لمجموعة من الأدوية تُسمى مثبطات أروماتاز. وهي لمعالجة سرطان الثدي الهرموني (أو &quot;الغدد الصم&quot;). وغالباً ما يُحفز نمو سرطان الثدي من قبل الإستروجينات والتي هي هرمونات جنسية أنثوية. يخفض&nbsp;<strong>زورولا</strong>&nbsp;كمية الإستروجين من خلال إعاقة أنزيم (&quot;أروماتاز&quot;) العامل في إنتاج الإستروجينات ولذلك يمكن له أن يعيق نمو سرطان الثدي الذي يحتاج نموه إلى الإستروجينات. ونتيجة لذلك تُبطئ خلايا الورم أو تُوقف النمو و/أو الانتشار إلى أجزاء أخرى من الجسم.</p><p dir="RTL"><strong>لأجل ماذا يُستخدم زورولا</strong></p><p dir="RTL">يُستخدم&nbsp;<strong>زورولا</strong>&nbsp;لمعالجة سرطان الثدي لدى النساء الذي دخل من خلال انقطاع الطمث، أي توقّف العادة الشهرية.</p><p dir="RTL">ويُستخدم لمنع حدوث السرطان مرة أخرى. يمكن استخدامه كمعالجة أولية قبل جراحة سرطان الثدي في حال لم تكن الجراحة الفورية مناسبة, أو يمكن استخدامه كمعالجة أولية بعد جراحة سرطان الثدي أو بعد المعالجة لمدة خمس سنوات بدواء تاميكسوفين. ويُستخدم&nbsp;<strong>زورولا</strong>&nbsp;لمنع انتشار ورم الثدي إلى أجزاء أخرى من الجسم لدى المرضى المصابين بسرطان ثدي متقدم.</p><p dir="RTL">إذا كان لديك أية أسئلة حول طريقة عمل&nbsp;<strong>زورولا</strong>&nbsp;أو لماذا وُصِف هذا الدواء لك, اسأل طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اتّبع تعليمات الطبيب بكل دقة. فقد تختلف عن المعلومات العامة التي في هذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تأخذ زورولا</strong></p><p dir="RTL">- إذا كنت تتحسس من ليتروزول أو من أية مكونات أخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">- إذا كنتِ لازلتِ لديكِ العادة الشهرية، أي إذا لم تتخطي بعد فترة انقطاع الطمث.&nbsp;</p><p dir="RTL">- إذا كنتِ حاملاً.</p><p dir="RTL">- إذا كنتِ مرضعةً.</p><p dir="RTL">إذا انطبقَ عليكِ أيّاً من هذه الأحوال,&nbsp;<strong>لا تأخذي هذا الدواء وتحدّثي إلى طبيبكِ</strong>.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المحاذير والاحتياطات</strong></p><p dir="RTL">تحدّث إلى طبيبك أو الصيدلي قبل تناول&nbsp;<strong>زورولا</strong>.</p><p dir="RTL">- إذا كان لديك مرض كلوي شديد.</p><p dir="RTL">- إذا كان لديك مرض كبدي شديد.</p><p dir="RTL">- إذا كان لديك تاريخ هشاشة عظام أو كسور في العظام (راجع أيضاً &quot;المتابعة أثناء المعالجة بدواء&nbsp;<strong>زورولا</strong>&quot; في القسم 3).</p><p dir="RTL">إذا انطبق عليك أيّاً من هذه الحالات,&nbsp;<strong>أخبر طبيبك</strong>. سوف يأخذ طبيبك هذا الأمر بالاعتبار أثناء معالجتك بدواء&nbsp;<strong>زورولا</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون (دون 18 سنة)</strong></p><p dir="RTL">يجب أن لا يَستخدم الأطفال والمراهقين هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأشخاص الأكبر (65 سنة فما فوق)</strong></p><p dir="RTL">يمكن استخدام هذا الدواء لدى الأشخاص بعمر 65 سنة فما فوق بنفس جرعة الكبار الآخرين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية أخرى وزورولا</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول, قد تناولت مؤخراً, أو يمكن أن تتناول أية أدوية أخرى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL"><strong>-&nbsp;</strong>عليكِ أن تستخدمي&nbsp;<strong>زورولا</strong>&nbsp;فقط عندما تتخطينَ فترة انقطاع الطمث. ومع ذلك, ينبغي على طبيبكِ أن يبحث معكِ حول استعمال موانع الحمل الفعالة, حيث لا زلتِ من المحتمل أن تُصبحي حاملاً أثناء المعالجة بدواء&nbsp;<strong>زورولا</strong>.</p><p dir="RTL">- يجب أن لا تأخذي&nbsp;<strong>زورولا</strong>&nbsp;إذا كنتِ حاملاً أو مرضعةً لأن ذلك يمكن أن يؤذي الطفل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة السيارات واستخدام الآلات</strong></p><p dir="RTL">إذا شعرت بدوخة, تعب, نعاس أو متوعكة بشكل عام, فلا تقود السيارة أو تُشغل أية أدوات أو آلات إلى أن تشعر بأنك بحالة طبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي زورولا على اللاكتوز</strong></p><p dir="RTL">يحتوي زورولا على اللاكتوز (سكر اللبن). فإذا أخبرك الطبيب أنك عديم التحمل لبعض السكريات, اتصل بطبيبك قبل أخذ هذا دواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائماً كما أخبرك طبيبك أو الصيدلي تماماً. تحقّق مع طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">الجرعة الموصى بها هي قرص واحد من&nbsp;<strong>زورولا</strong>&nbsp;يُؤخذ مرة واحدة في اليوم. وإن أخذ&nbsp;<strong>زورولا</strong>&nbsp;بنفس الوقت من كل يوم سوف يساعدك على تذكّر موعد تناولك لقرصك الدوائي.</p><p dir="RTL">يمكن أخذ القرص مع أو بدون الطعام, ويجب أن يُبلع بكامله مع كأس من الماء أو مع سائل آخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>إلى متى ستتناول&nbsp;<strong>زورولا</strong></u></p><p dir="RTL">استمر بتناول&nbsp;<strong>زورولا</strong>&nbsp;كل يومٍ طيلة المدة التي أخبرك طبيبك بها. قد تحتاج لأخذ الدواء لمدة أشهر أو حتى سنوات. فإذا كان لديك أية أسئلة حول المدة التي ينبغي عليك الاستمرار بها في أخذ&nbsp;<strong>زورولا</strong>, تحدّث إلى طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>المتابعة أثناء المعالجة بدواء&nbsp;<strong>زورولا</strong></u></p><p dir="RTL">يجب أن تأخذ هذا الدواء فقط تحت إشراف طبي صارم. سوف يراقب طبيبك بانتظام حالتك للتحقق فيما إذا كانت المعالجة ذات تأثير صحيح.</p><p dir="RTL">يمكن أن يسبب&nbsp;<strong>زورولا</strong>&nbsp;ترققاً أو تلفاً في عظامك (هشاشة العظام) بسب انخفاض الإستروجينات في جسمك. يمكن أن يقرر طبيبك قياس كثافة عظمك (طريقة لمراقبة هشاشة العظام) قبل, أثناء وبعد المعالجة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أخذت زورولا أكثر مما يجب</strong></p><p dir="RTL">إذا أخذت كمية كبيرة جداً من&nbsp;<strong>زورولا</strong>, أو إذا أخذ شخص آخر أقراصك بالصدفة, اتصل بالطبيب أو المشفى فوراً لأخذ المشورة. وأرِهم عبوة الأقراص. قد تكون المعالجة الطبية ضرورية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تأخذ زورولا</strong></p><p dir="RTL">- إذا حان تقريباً وقت الجرعة التالية (أي في غضون 2 أو 3 ساعات), تجاوز الجرعة المنسية, وتناول الجرعة التالية في الوقت المناسب لك.</p><p dir="RTL">- وغير ذلك, تناول الجرعة حالما تتذكرها, وبعد ذلك تناول الجرعة التالية كما اعتدت أن تأخذها.</p><p dir="RTL">- لا تأخذ جرعة مضاعفة للتعويض عن الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول زورولا</strong></p><p dir="RTL">لا تتوقف عن تناول&nbsp;<strong>زورولا</strong>&nbsp;ما لم يطلب إليك طبيبك ذلك. راجع أيضاً القسم السابق &quot;إلى متى ستتناول&nbsp;<strong>زورولا</strong>&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية, يمكن أن يسبب هذا الدواء تأثيرات جانبية, وإن كان لا تحدث لكل شخص.</p><p dir="RTL">معظم التأثيرات الجانبية خفيفة إلى معتدلة وسوف تختفي عموماً بعد بضعة أيام إلى بضعة أسابيع من المعالجة.</p><p dir="RTL">بعض هذه التأثيرات الجانبية, مثل الهبّات الساخنة, سقوط الشعر أو النزف المهبلي, قد تكون ناجمة عن نقص الإستروجينات في جسمك.</p><p dir="RTL">لا تقلق من قائمة التأثيرات الجانبية المحتملة هذه. فقد لا تواجه أيّاً منها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بعض التأثيرات الجانبية قد تكون خطيرة:</strong></p><p dir="RTL"><strong>تأثيرات جانبية نادرة أو غير شائعة&nbsp;</strong>(أي يمكن أن تؤثر في ما بين 1 إلى 100 من كل 10,000 مريض):</p><p dir="RTL">- ضعف, شلل أو فقدان إحساس في أي جزء من الجسم (خاصة الذراع أو الساق)، فقدان التناسق، غثيان أو صعوبة في التكلم أو التنفس (علامة على حدوث اضطراب في الدماغ، مثل السكتة الدماغية).</p><p dir="RTL">- ألم شديد مفاجئ في الصدر (علامة اضطراب القلب).</p><p dir="RTL">- صعوبة في التنفس, ألم في الصدر, إغماء، تسرع ضربات القلب، تلوّن مائل للزرقة في الجلد, أو ألم مفاجئ في الذراع, الساق أو القدم (علامات احتمال تشكل جلطة دموية).</p><p dir="RTL">- تورُّم أو احمرار على طول أحد الأوردة الذي يكون سريع العطب جداً<strong>&nbsp;</strong>ويحتمل<strong>&nbsp;أن&nbsp;</strong>يكون مؤلماً عند لمسه.</p><p dir="RTL">- حمى شديدة, بردية أو تقرحات بالفم ناجمة عن التهابات (نقص خلايا الدم البيضاء).</p><p dir="RTL">- رؤية مشوشة شديدة ومستمرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك فوراً, إذا حدث معك أيّاً مما سبق.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يجب عليكِ أيضاً أن تُخبر الطبيب فوراً إذا واجهت أيّاً من الأعراض التالية أثناء المعالجة بدواء&nbsp;<strong>زورولا</strong>:</p><p dir="RTL">- تورُّم وخاصة في الوجه والحلق (علامات حدوث رد فعل تحسسي).</p><p dir="RTL">- جلد وعيون صفراء، غثيان، فقدان شهية، بول داكن اللون (علامات التهاب الكبد).</p><p dir="RTL">- طفح جلدي، جلد أحمر، تبثر الشفتين, العينين أو الفم، تقشر الجلد، حمى (علامات إضطراب جلدي).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تأثيرات جانبية أخرى:</u></p><p dir="RTL"><em>شائعة جداً (يمكن أن تؤثر في أكثر من 1 من كل 10 أشخاص)</em></p><p dir="RTL">- هبّات ساخنة.</p><p dir="RTL">- زيادة مستوى الكوليسترول (ارتفاع مستوى الكوليسترول في الدم).</p><p dir="RTL">- إعياء.</p><p dir="RTL">- تعرق متزايد.</p><p dir="RTL">- ألم في العظام والمفاصل (التهاب المفاصل).</p><p dir="RTL">إذا تأثرت بشدة من أيٍّ من هذه التأثيرات, أخبر طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>شائعة (يمكن أن تؤثر حتى في 1 من كل 10 أشخاص)</em></p><p dir="RTL">- طفح جلدي.</p><p dir="RTL">- وجع رأس.</p><p dir="RTL">- دوخة.</p><p dir="RTL">- وعكة صحية (شعور بتوعك عموماً).</p><p dir="RTL">- اضطرابات معدية معوية مثل&nbsp;&nbsp;إقياء، عسر هضم إمساك، إسهال.</p><p dir="RTL">- تزايد أو فقدان في الشهية.</p><p dir="RTL">- ألم في العضلات.</p><p dir="RTL">- ترقق أو تلف العظام (هشاشة العظام), يؤدي إلى كسور في العظم في بعض الحالات (راجع أيضاً &quot;المتابعة أثناء المعالجة بدواء&nbsp;<strong>زورولا</strong>&quot; في القسم 3).</p><p dir="RTL">- تورُّم الذراعين، اليدين, القدمين، الكاحلين (استسقاء).</p><p dir="RTL">- اكتئاب.</p><p dir="RTL">- زيادة الوزن.</p><p dir="RTL">- سقوط الشعر.</p><p dir="RTL">- ضغط دم مرتفع (ارتفاع الضغط).</p><p dir="RTL">- ألم في البطن.</p><p dir="RTL">- جلد جاف.</p><p dir="RTL">- نزف مهبلي.</p><p dir="RTL">إذا تأثرت بشدة من أيٍّ من هذه التأثيرات, أخبر طبيبك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><em>غير&nbsp;&nbsp;شائعة (يمكن أن تؤثر حتى في 1 من كل 100 شخص)</em></p><p dir="RTL">- اضطرابات عصبية مثل قلق, نرفزة, اهتياج, نعاس, مشاكل في الذاكرة, تخدر, أرق.</p><p dir="RTL">- اعتلال الإحساس خاصة في اللمس.</p><p dir="RTL">- اضطرابات عينية كالرؤية المشوشة, وتهيج العينين.</p><p dir="RTL">- خفقان, تسرع ضربات القلب.</p><p dir="RTL">- اضطرابات جلدية كالحكة0(طفح جلدي).</p><p dir="RTL">- سيلان أو جفاف مهبلي.</p><p dir="RTL">- تصلب مفاصل (التهاب المفاصل).</p><p dir="RTL">- ألم في الثديين.</p><p dir="RTL">- حمى.</p><p dir="RTL">- عطش، اضطراب التذوق، فم جاف.</p><p dir="RTL">- جفاف الأغشية المخاطية.</p><p dir="RTL">- نقص الوزن.</p><p dir="RTL">- التهاب المجاري البولية، زيادة تكرار التبول.</p><p dir="RTL">- سعال.</p><p dir="RTL">- تزايد مستوى الأنزيمات.</p><p dir="RTL">إذا تأثرت بشدة من أيٍّ من هذه التأثيرات, أخبر طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن التأثيرات الجانبية</strong></p><p dir="RTL">إذا حدث لك أية تأثيرات جانبية, تحدث إلى طبيبك أو الصيدلي. ويشمل ذلك أية تأثيرات جانبية محتملة غير مدرجة في هذه النشرة. ويمكنك أيضاً أن تبلغ عن التأثيرات الجانبية مباشرة عن طريق المركز الوطني للأدوية والسلامة الدوائية&nbsp;(NBC)&nbsp;+966-11-2038222. التحويلات:&nbsp;2317 - 2356 - 2353 - 2354 - 2334 - 2340. الهاتف المجاني:&nbsp;8002490000. البريد الإلكتروني:&nbsp;npc.drug@sfda.gov.sa.</p><p dir="RTL">ويمكنك بالإبلاغ عن التأثيرات الجانبية أن تُساعد في إعطاء المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن رؤية ومتناول الأطفال.</p><p dir="RTL">لا يتطلب هذا المنتج الدوائي أية شروط خاصة للتخزين.</p><p dir="RTL">لا تستخدم&nbsp;<strong>زورولا</strong>&nbsp;بعد انتهاء صلاحيته المذكورة على العبوة واللصاقة.</p><p dir="RTL">يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أية أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. هذه التدابير سوف تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- المادة الفعالة هي ليتروزول. يحتوي كل قرص ملبس بفلم 2,5 ملغ ليتروزول.</p><p dir="RTL">- المكونات الآخرى هي:</p><p dir="RTL"><em>قلب القرص :</em>&nbsp;&nbsp;أحادي هيدرات اللاكتوز، نشاء الذرة، غليكولات نشاء الصوديوم نوع&nbsp;A,&nbsp;مايكروكريستالين سيليلوز، سيليكا لا مائية غروية، ستيآرات المغنيزيوم.</p><p dir="RTL"><em>غلاف القرص:</em>&nbsp;بولي فينيل الكحول، تلك، ماكروغول 3350، ثاني أوكسيد التيتانيوم (E171),&nbsp;وأوكسيد الحديد الأصفر (E172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>زورولا</strong>&nbsp;2,5ملغ هو أقراص عدسية مستديرة صفراء مغلفة بفلم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>أحجام العبوات:</em></p><p dir="RTL">عبوات بلاستيكية من: 10 ، 14 ، 20 , 28 ، 30 ، 50 ، 60 ، 84 , 100 و120 قرصاً مغلفاً بفلم.</p><p dir="RTL">عبوات الأقراص مغلقة بغطاء لولبي مقاوم للأطفال: 30 ، 100 قرصاً مغلفاً بفلم.</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الصانع</strong></p><p dir="RTL">مجموعة أكتافيس بي تي سي إيف</p><p dir="RTL">ريكيافيكورفيغور 76 - 78</p><p dir="RTL">220 هافنارفيوردور</p><p dir="RTL">إيرلندا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حامل ترخيص التسويق</strong></p><p dir="RTL">شركة تداوي الطبية الحيوية</p><p dir="RTL">شارع أولايا,</p><p dir="RTL">الرياض</p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة آخر مرة في 06/2016.



        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xorola 2.5 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 2.5 mg letrozole.
Excipients with known effect: Each tablet contains 58.4 mg lactose as lactose monohydrate. 
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet
Xorola 2.5 mg are yellow, round, lenticular, film-coated tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Therapeutic&nbsp;indications</strong></p><p><strong>&nbsp;</strong></p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Adjuvant&nbsp;treatment&nbsp;of&nbsp;postmenopausal&nbsp;women&nbsp;with&nbsp;hormone&nbsp;receptor&nbsp;positive&nbsp;invasive&nbsp;early breast cancer.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Extended&nbsp;adjuvant&nbsp;treatment&nbsp;of&nbsp;hormone-dependent&nbsp;invasive&nbsp;breast&nbsp;cancer&nbsp;in&nbsp;postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->First-line&nbsp;treatment&nbsp;in&nbsp;postmenopausal&nbsp;women&nbsp;with&nbsp;hormone-dependent&nbsp;advanced&nbsp;breast&nbsp;cancer.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Advanced&nbsp;breast&nbsp;cancer&nbsp;after&nbsp;relapse&nbsp;or&nbsp;disease&nbsp;progression,&nbsp;in&nbsp;women&nbsp;with&nbsp;natural&nbsp;or&nbsp;artificially induced postmenopausal endocrine status, who have&nbsp;previously been treated with anti-&nbsp;oestrogens.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Neo-adjuvant treatment of postmenopausal women with hormone receptor positive, HER-2 negative&nbsp;breastcancer&nbsp;where&nbsp;chemotherapy&nbsp;is&nbsp;not&nbsp;suitable&nbsp;and&nbsp;immediate&nbsp;surgery&nbsp;not&nbsp;indicated.</p><p>&nbsp;</p><p>Efficacy&nbsp;has&nbsp;not&nbsp;been&nbsp;demonstrated&nbsp;in&nbsp;patients&nbsp;with&nbsp;hormone&nbsp;receptor&nbsp;negative&nbsp;breast&nbsp;cancer.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em>Adults&nbsp;and&nbsp;elderly&nbsp;patients</em></p><p>The&nbsp;recommended&nbsp;dose&nbsp;of&nbsp;letrozole&nbsp;is&nbsp;2.5&nbsp;mg&nbsp;once&nbsp;daily.&nbsp;No&nbsp;dose&nbsp;adjustment&nbsp;is&nbsp;required&nbsp;for&nbsp;elderly&nbsp;patients.</p><p>&nbsp;</p><p>In&nbsp;patients&nbsp;with&nbsp;advanced&nbsp;or&nbsp;metastatic breast&nbsp;cancer,&nbsp;treatment&nbsp;with&nbsp;letrozole&nbsp;should&nbsp;continue&nbsp;until tumour progression if evident.</p><p>&nbsp;</p><p>In&nbsp;the&nbsp;adjuvant&nbsp;and&nbsp;extended&nbsp;adjuvant&nbsp;setting,&nbsp;treatment&nbsp;with&nbsp;Xorola&nbsp;should&nbsp;continue&nbsp;for&nbsp;5&nbsp;years&nbsp;or until tumour relapse occurs, whichever is first.</p><p>&nbsp;</p><p>In&nbsp;the&nbsp;adjuvant&nbsp;setting&nbsp;a&nbsp;sequential&nbsp;treatment&nbsp;schedule&nbsp;(letrozole&nbsp;2&nbsp;years&nbsp;followed&nbsp;by&nbsp;tamoxifen&nbsp;3 years) could also be considered (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p>In the neoadjuvant&nbsp;setting, treatment with Xorola&nbsp;could&nbsp;be continued&nbsp;for 4 to 8 months&nbsp;in order to establish&nbsp;optimal&nbsp;tumourreduction.&nbsp;If&nbsp;the&nbsp;response&nbsp;is&nbsp;not&nbsp;adequate,&nbsp;treatment&nbsp;with&nbsp;Xorola&nbsp;should&nbsp;be discontinued and surgery scheduled and/or further treatment options discussed with the patient.</p><p><em>Paediatric&nbsp;population</em></p><p>Xorola is not recommended&nbsp;for use in children and adolescents.&nbsp;The safety and efficacy ofXorola in children&nbsp;andadolescents&nbsp;aged&nbsp;up&nbsp;to&nbsp;17&nbsp;years&nbsp;have&nbsp;not&nbsp;been&nbsp;established.&nbsp;Limited&nbsp;data&nbsp;are&nbsp;available&nbsp;but no recommendation on a posology can be made.</p><p>&nbsp;</p><p><em>Renal&nbsp;impairment</em></p><p>No dosage adjustment of Xorola&nbsp;is required for patients with renal insufficiency&nbsp;with creatinine clearance&nbsp;&ge;10ml/min.&nbsp;Insufficient&nbsp;data&nbsp;are&nbsp;available&nbsp;in&nbsp;cases&nbsp;of&nbsp;renal&nbsp;insufficiency&nbsp;with&nbsp;creatinine clearance lower than 10 ml/min (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Hepatic&nbsp;impairment</em></p><p>No dose adjustment&nbsp;of Xorola is required for patients&nbsp;with mild to moderate hepatic insufficiency (Child-Pugh&nbsp;A or B). Insufficient&nbsp;data are available for patients with severe hepatic impairment. Patients&nbsp;with&nbsp;severe&nbsp;hepaticimpairment&nbsp;(Child-Pugh&nbsp;C)&nbsp;require&nbsp;close&nbsp;supervision&nbsp;(see&nbsp;sections&nbsp;4.4&nbsp;and&nbsp;5.2).</p><p>&nbsp;</p><p><u>Method&nbsp;of&nbsp;administration</u></p><p>Xorola&nbsp;should&nbsp;be&nbsp;taken&nbsp;orally&nbsp;and&nbsp;can&nbsp;be&nbsp;taken&nbsp;with&nbsp;or&nbsp;without&nbsp;food.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
-	Premenopausal endocrine status
-	Pregnancy (see section 4.6)
-	Breastfeeding (see section 4.6)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Menopausal&nbsp;status</u></p><p>In&nbsp;patients&nbsp;whose&nbsp;menopausal&nbsp;status&nbsp;is&nbsp;unclear,&nbsp;luteinising&nbsp;hormone&nbsp;(LH),&nbsp;follicle-stimulating&nbsp;hormone (FSH) and/or oestradiol&nbsp;levels should be measured before initiating&nbsp;treatment with Xorola. Only women of postmenopausalendocrine status should receive Xorola.</p><p>&nbsp;</p><p><u>Renal&nbsp;impairment</u></p><p>Letrozole&nbsp;has&nbsp;not&nbsp;been&nbsp;investigated&nbsp;in&nbsp;a&nbsp;sufficient&nbsp;number&nbsp;of&nbsp;patients&nbsp;with&nbsp;creatinine&nbsp;clearance&nbsp;lower than 10 ml/min. The potential risk/benefit to such patients should be carefully considered before administration of Xorola.</p><p>&nbsp;</p><p><u>Hepatic&nbsp;impairment</u></p><p>In&nbsp;patients&nbsp;with&nbsp;severe&nbsp;hepatic&nbsp;impairment&nbsp;(Child-Pugh&nbsp;C),&nbsp;systemic&nbsp;exposure&nbsp;and&nbsp;terminal&nbsp;half-life wereapproximately&nbsp;doubled&nbsp;compared&nbsp;to&nbsp;healthy&nbsp;volunteers.&nbsp;Such&nbsp;patients&nbsp;should&nbsp;therefore&nbsp;be&nbsp;kept under close supervision (see section 5.2).</p><p>&nbsp;</p><p><u>Bone&nbsp;effects</u></p><p>Xorola&nbsp;is a potent&nbsp;oestrogen-lowering&nbsp;agent.&nbsp;Women&nbsp;with&nbsp;a history&nbsp;of&nbsp;osteoporosis&nbsp;and/or fractures,&nbsp;or who are at increased risk of osteoporosis,&nbsp;should have their bone mineral density&nbsp;formally assessed prior to the commencementof adjuvant and extended adjuvant treatment and monitored during and following&nbsp;treatment with letrozole. Treatment or prophylaxis&nbsp;for osteoporosis&nbsp;should be initiated as appropriate&nbsp;and&nbsp;carefully&nbsp;monitored.&nbsp;In&nbsp;the&nbsp;adjuvant&nbsp;setting&nbsp;asequential&nbsp;treatment&nbsp;schedule&nbsp;(letrozole&nbsp;2 years&nbsp;followed&nbsp;by&nbsp;tamoxifen&nbsp;3&nbsp;years)&nbsp;could&nbsp;also&nbsp;be&nbsp;considered&nbsp;depending&nbsp;onthe&nbsp;patient`s&nbsp;safety&nbsp;profile (see sections 4.2, 4.8 and 5.1).</p><p>&nbsp;</p><p><u>Other&nbsp;warnings</u></p><p>Co-administration&nbsp;of&nbsp;Xorola&nbsp;with&nbsp;tamoxifen,&nbsp;other&nbsp;anti-oestrogens&nbsp;or&nbsp;oestrogen-containing&nbsp;therapies should be avoided as these substances may diminish the pharmacological&nbsp;action of letrozole (see section 4.5).</p><p>As&nbsp;the&nbsp;tablets&nbsp;contain&nbsp;lactose,&nbsp;Xorola&nbsp;is&nbsp;not&nbsp;recommended&nbsp;for&nbsp;patients&nbsp;with&nbsp;rare&nbsp;hereditary&nbsp;problems of galactose intolerance, of severe lactase deficiency or of glucose-galactose malabsorption.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Metabolism&nbsp;of&nbsp;letrozole&nbsp;is&nbsp;partly&nbsp;mediated&nbsp;via&nbsp;CYP2A6&nbsp;and&nbsp;CYP3A4.&nbsp;Cimetidine,&nbsp;a&nbsp;weak,&nbsp;unspecific inhibitor of CYP450&nbsp;enzymes, did not affect the plasma concentrations&nbsp;of letrozole.&nbsp;The effect of potent CYP450 inhibitors is unknown.</p><p>&nbsp;</p><p>There is no clinical experience&nbsp;to date on the use of Xorola&nbsp;in combination&nbsp;with oestrogens&nbsp;or other anticancer agents, other than tamoxifen. Tamoxifen, other anti-oestrogens or oestrogen-containing therapies may diminish the pharmacological&nbsp;action of letrozole. In addition, co-administration&nbsp;of tamoxifen with&nbsp;letrozole&nbsp;has been&nbsp;shown&nbsp;to substantially&nbsp;decrease&nbsp;plasma&nbsp;concentrations&nbsp;of&nbsp;letrozole. Co-&nbsp;administration&nbsp;of&nbsp;letrozole&nbsp;with&nbsp;tamoxifen,&nbsp;other&nbsp;anti-oestrogens&nbsp;or&nbsp;oestrogens&nbsp;should&nbsp;be&nbsp;avoided.</p><p>&nbsp;</p><p><em>In vitro,&nbsp;</em>letrozole inhibits the cytochrome P450 isoenzymes 2A6 and, moderately, 2C19, but the clinical relevance is unkown. Caution is therefore indicated when giving letrozole&nbsp;contomitantly&nbsp;with medicinal&nbsp;products&nbsp;whoseelimination&nbsp;is&nbsp;mainly&nbsp;dependent&nbsp;on&nbsp;these&nbsp;isoenzymes&nbsp;and&nbsp;whose&nbsp;therapeutic index is narrow (e.g. phenytoin, clopidrogel).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women&nbsp;of&nbsp;perimenopausal&nbsp;status&nbsp;or&nbsp;child-bearing&nbsp;potential</u></p><p>Xorola should only be used in women with a clearly established&nbsp;postmenopausal&nbsp;status (see section 4.4).&nbsp;As&nbsp;there&nbsp;arereports&nbsp;of&nbsp;women&nbsp;regaining&nbsp;ovarian&nbsp;function&nbsp;during&nbsp;treatment&nbsp;with&nbsp;letrozole&nbsp;despite&nbsp;a clear postmenopausal&nbsp;status at start of therapy, the physician needs to discuss adequate contraception when necessary.</p><p><u>Pregnancy</u></p><p>Based on human experience in which there have been isolated cases of birth defects (labial fusion, ambiguous genitalia), Letrozole may cause congenital malformations when administered during pregnancy. Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>Xorola&nbsp;is&nbsp;contraindicated&nbsp;during&nbsp;pregnancy&nbsp;(see&nbsp;sections&nbsp;4.3&nbsp;and&nbsp;5.3).&nbsp;</p><p><u>Breastfeeding</u></p><p>It&nbsp;is&nbsp;unknown&nbsp;whether&nbsp;letrozole&nbsp;and&nbsp;its&nbsp;metabolites&nbsp;are&nbsp;excreted&nbsp;in&nbsp;human&nbsp;milk.&nbsp;A&nbsp;risk&nbsp;to&nbsp;the&nbsp;newborns/infants&nbsp;cannot&nbsp;be&nbsp;excluded.</p><p>Xorola&nbsp;is&nbsp;contraindicated&nbsp;during&nbsp;breastfeeding&nbsp;(see&nbsp;section&nbsp;4.3).</p><p>&nbsp;<u>Fertility</u></p><p>The&nbsp;pharmacological&nbsp;action&nbsp;of&nbsp;letrozole&nbsp;is&nbsp;to&nbsp;reduce&nbsp;oestrogen&nbsp;production&nbsp;by&nbsp;aromatase&nbsp;inhibition.&nbsp;In premenopausalwomen, the inhibition of oestrogen synthesis leads to feedback increases in gonadotropin (LH, FSH) levels. Increased FSH levels in turn stimulate follicular growth, and can induce ovulation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Xorola&nbsp;has&nbsp;minor&nbsp;influence&nbsp;on&nbsp;the&nbsp;ability&nbsp;to&nbsp;drive&nbsp;and&nbsp;use&nbsp;machines.&nbsp;Since&nbsp;fatigue&nbsp;and&nbsp;dizziness&nbsp;have been observed with the use of letrozole&nbsp;and somnolence&nbsp;has been reported uncommonly,&nbsp;caution is advised when driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary&nbsp;of&nbsp;the&nbsp;safety&nbsp;profile</u></p><p>&nbsp;</p><p>The&nbsp;frequencies&nbsp;of&nbsp;adverse&nbsp;reactions&nbsp;for&nbsp;letrozole&nbsp;are&nbsp;mainly&nbsp;based&nbsp;on&nbsp;data&nbsp;collected&nbsp;from&nbsp;clinical&nbsp;trials.</p><p>&nbsp;</p><p>Up to approximately&nbsp;one third of the patients&nbsp;treated with letrozole&nbsp;in the metastatic&nbsp;setting&nbsp;and approximately&nbsp;80%of&nbsp;the&nbsp;patients&nbsp;in&nbsp;the&nbsp;adjuvant&nbsp;setting&nbsp;as&nbsp;well&nbsp;as&nbsp;in&nbsp;the&nbsp;extended&nbsp;adjuvant&nbsp;setting experienced&nbsp;adverse reactions. The majority of the adverse reactions occurred during the first few weeks of treatment.</p><p>The&nbsp;most&nbsp;frequently&nbsp;reported&nbsp;adverse&nbsp;reactions&nbsp;in&nbsp;clinical&nbsp;studies&nbsp;were&nbsp;hot&nbsp;flushes, hypercholesterolaemia, arthralgia, fatigue, increased sweating and nausea.</p><p>Important additional adverse reactions&nbsp;that may occur with letrozole are: skeletal events such as osteoporosis and/or bone fractures and cardiovascular events (including cerebrovascular and thromboembolic&nbsp;events).&nbsp;The&nbsp;frequencycategory&nbsp;for&nbsp;these&nbsp;adverse&nbsp;reactions&nbsp;is&nbsp;described&nbsp;in&nbsp;Table&nbsp;1.</p><p><u>Tabulated&nbsp;listing&nbsp;of&nbsp;adverse&nbsp;reactions</u></p><p>The&nbsp;frequencies&nbsp;of&nbsp;adverse&nbsp;reactions&nbsp;for&nbsp;letrozole&nbsp;are&nbsp;mainly&nbsp;based&nbsp;on&nbsp;data&nbsp;collected&nbsp;from&nbsp;clinical&nbsp;trials.</p><p>The&nbsp;following&nbsp;adverse&nbsp;drug&nbsp;reactions,&nbsp;listed&nbsp;in&nbsp;Table&nbsp;1,&nbsp;were&nbsp;reported&nbsp;from&nbsp;clinical&nbsp;studies&nbsp;and&nbsp;from post- marketing experience with letrozole:</p><p><strong>Table&nbsp;1</strong></p><p><strong>Adverse&nbsp;reactions&nbsp;are&nbsp;ranked&nbsp;under&nbsp;headings&nbsp;of&nbsp;frequency,&nbsp;the&nbsp;most&nbsp;frequent&nbsp;first,&nbsp;using&nbsp;the&nbsp;following convention:&nbsp;very common &ge;10%, common&nbsp;&ge;1% to &le;10%, uncommon&nbsp;&ge;0.1%&nbsp;to &le;1%, rare&nbsp;&nbsp;&ge;0.01%&nbsp;to&nbsp;&le;0.1%,&nbsp;very&nbsp;rare&nbsp;&le;0.01%,&nbsp;not&nbsp;known&nbsp;(cannot&nbsp;be&nbsp;estimated&nbsp;from&nbsp;the&nbsp;available&nbsp;data)</strong></p><p>&nbsp;</p><p><strong>Infections&nbsp;and&nbsp;infestations</strong></p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Urinary&nbsp;tract&nbsp;infection</p><p><strong>Neoplasms,&nbsp;benign,&nbsp;malignant&nbsp;and&nbsp;unspecified&nbsp;(including&nbsp;cysts&nbsp;and&nbsp;polyps)</strong></p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tumour&nbsp;pain<sup>1</sup></p><p><strong>Blood&nbsp;and&nbsp;the&nbsp;lymphatic&nbsp;system&nbsp;disorders</strong></p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Leukopenia</p><p><strong>Immune&nbsp;system&nbsp;disorders</strong></p><p>Not&nbsp;known:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anaphylactic&nbsp;reaction</p><p><strong>Metabolism&nbsp;and&nbsp;nutrition&nbsp;disorders</strong></p><p>Very&nbsp;common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hypercholesterolaemia</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anorexia,&nbsp;appetite&nbsp;increase</p><p><strong>Psychiatric&nbsp;disorders</strong></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depression</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anxiety&nbsp;(including&nbsp;nervousness),&nbsp;irritability</p><p><strong>Nervous&nbsp;system&nbsp;disorders</strong></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headache,&nbsp;dizziness</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Somnolence, insomnia, memory impairment, dysaesthesia (including paraesthesia,hypoaesthesia),&nbsp;taste&nbsp;disturbance,&nbsp;cerebrovascular&nbsp;accident</p><p><strong>Eye&nbsp;disorders</strong></p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cataract,&nbsp;eye&nbsp;irritation,&nbsp;blurred&nbsp;vision</p><p><strong>Cardiac&nbsp;disorders</strong></p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Palpitations<sup>1</sup>, tachycardia, ischaemic cardiac events(including&nbsp;new or worseningangina,&nbsp;angina&nbsp;requiring&nbsp;surgery,&nbsp;myocardial&nbsp;infarction&nbsp;and myocardial&nbsp;ischaemia)</p><p><strong>Vascular&nbsp;disorders</strong></p><p>Very&nbsp;common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hot&nbsp;flushes</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hypertension</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thrombophlebitis&nbsp;(including&nbsp;superficial&nbsp;and&nbsp;deep&nbsp;vein&nbsp;thrombophlebitis)&nbsp;Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pulmonary embolism, arterial thrombosis, cerebrovascular infarction</p><p><strong>Respiratory,&nbsp;thoracic&nbsp;and&nbsp;mediastinal&nbsp;disorders</strong></p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dyspnoea,&nbsp;cough</p><p><strong>Gastrointestinal&nbsp;disorders</strong></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nausea,&nbsp;dyspepsia<sup>1</sup>,&nbsp;constipation,&nbsp;abdominal&nbsp;pain,&nbsp;diarrhoea,&nbsp;vomiting&nbsp;Uncommon:&nbsp;&nbsp;Dry mouth, stomatitis<sup>1</sup></p><p><strong>Hepatobiliary&nbsp;disorders</strong></p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increased&nbsp;hepatic&nbsp;enzymes</p><p>Not&nbsp;known:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hepatitis</p><p><strong>Skin&nbsp;and&nbsp;subcutaneous&nbsp;tissue&nbsp;disorders</strong></p><p>Very&nbsp;common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increased&nbsp;sweating</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alopecia,&nbsp;rash&nbsp;(including&nbsp;erythematous,&nbsp;maculopapular,&nbsp;psoriaform,&nbsp;and vesicular rash), dry skin</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pruritus,&nbsp;urticaria</p><p>Not&nbsp;known:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Angioedema,&nbsp;toxic&nbsp;epidermal&nbsp;necrolysis,&nbsp;erythema&nbsp;multiforme</p><p><strong>Musculoskeletal&nbsp;and&nbsp;connective&nbsp;tissue&nbsp;disorders</strong></p><p>Very&nbsp;common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Arthralgia</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Myalgia,&nbsp;bone&nbsp;pain<sup>1</sup>,&nbsp;osteoporosis,&nbsp;bone&nbsp;fractures</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Arthritis</p><p><strong>Renal&nbsp;and&nbsp;urinary&nbsp;disorders</strong></p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increased&nbsp;urinary&nbsp;frequency</p><p><strong>Reproductive&nbsp;system&nbsp;and&nbsp;breast&nbsp;disorders</strong></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vaginal&nbsp;bleeding</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vaginal&nbsp;discharge,&nbsp;vaginal&nbsp;dryness,&nbsp;breast&nbsp;pain</p><p><strong>General&nbsp;disorders&nbsp;and&nbsp;administration&nbsp;site&nbsp;conditions</strong></p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fatigue&nbsp;(including&nbsp;asthenia,&nbsp;malaise)&nbsp;</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Peripheral&nbsp;oedema</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General&nbsp;oedema,&nbsp;mucosal&nbsp;dryness,&nbsp;thirst,&nbsp;pyrexia</p><p><strong>Investigations</strong></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Weight&nbsp;increase</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Weight&nbsp;loss</p><p>----------------------------------------------------------------------------------------------</p><p><sup>1</sup>Adverse&nbsp;drug&nbsp;reactions&nbsp;reported&nbsp;only&nbsp;in&nbsp;the&nbsp;metastatic&nbsp;setting</p><p>&nbsp;</p><p>Some&nbsp;adverse&nbsp;reactions&nbsp;have&nbsp;been&nbsp;reported&nbsp;with&nbsp;notably&nbsp;different&nbsp;frequencies&nbsp;in&nbsp;the&nbsp;adjuvant&nbsp;treatment setting. The following&nbsp;tables provide information on significant differences&nbsp;in letrozole versus tamoxifen monotherapy and in the letrozole-tamoxifen&nbsp;sequential treatment therapy:</p><p><strong>Table 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjuvant&nbsp;letrozole&nbsp;monotherapy&nbsp;versus&nbsp;tamoxifen&nbsp;monotherapy&nbsp;&ndash;&nbsp;adverse&nbsp;events with significant differences</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Letrozole,&nbsp;incidence&nbsp;rate</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen,&nbsp;incidence&nbsp;rate</strong></p></td></tr><tr><td style="vertical-align:top"><p>Bone&nbsp;fracture</p></td><td style="vertical-align:top"><p>10.1%&nbsp;(13.8%)</p></td><td style="vertical-align:top"><p>7.1%&nbsp;(10.5%)</p></td></tr><tr><td style="vertical-align:top"><p>Osteoporosis</p></td><td style="vertical-align:top"><p>5.1%&nbsp;(5.1%)</p></td><td style="vertical-align:top"><p>2.7%&nbsp;(2.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Thromboembolic&nbsp;events</p></td><td style="vertical-align:top"><p>2.1%&nbsp;(2.9%)</p></td><td style="vertical-align:top"><p>3.6%&nbsp;(4.5%)</p></td></tr><tr><td style="vertical-align:top"><p>Myocardial&nbsp;infarction</p></td><td style="vertical-align:top"><p>1.0%&nbsp;(1.5%)</p></td><td style="vertical-align:top"><p>0.5%&nbsp;(1.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Endometrial&nbsp;hyperplasia&nbsp;/</p><p>endometrial&nbsp;cancer</p></td><td style="vertical-align:top"><p>0.2%&nbsp;(0.4%)</p></td><td style="vertical-align:top"><p>2.3%&nbsp;(2.9%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Note:&nbsp;Median&nbsp;duration&nbsp;of&nbsp;treatment&nbsp;60&nbsp;months.&nbsp;Reporting&nbsp;period&nbsp;includes&nbsp;treatment&nbsp;period&nbsp;plus&nbsp;30 days after stopping treatment.</p><p>Percentages&nbsp;in&nbsp;parentheses&nbsp;indicate&nbsp;event&nbsp;frequencies&nbsp;any&nbsp;time&nbsp;after&nbsp;randomisation,&nbsp;including&nbsp;post study treatment period. Median follow-up was 73 months.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sequential&nbsp;treatment&nbsp;versus&nbsp;letrozole&nbsp;monotherapy&nbsp;&ndash;&nbsp;adverse&nbsp;events&nbsp;with&nbsp;significant&nbsp;differences</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Letrozole&nbsp;monotherapy</strong></p></td><td style="vertical-align:top"><p><strong>Letrozole-&nbsp;&gt;tamoxifen</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen-&nbsp;&gt;letrozole</strong></p></td></tr><tr><td style="vertical-align:top"><p>Bone&nbsp;fractures</p></td><td style="vertical-align:top"><p>9.9%</p></td><td style="vertical-align:top"><p>7.6%*</p></td><td style="vertical-align:top"><p>9.6%</p></td></tr><tr><td style="vertical-align:top"><p>Endometrial&nbsp;proliferative</p><p>disorders</p></td><td style="vertical-align:top"><p>0.7%</p></td><td style="vertical-align:top"><p>3.4%**</p></td><td style="vertical-align:top"><p>1.7%**</p></td></tr><tr><td style="vertical-align:top"><p>Hypercholesterolaemia</p></td><td style="vertical-align:top"><p>52.5%</p></td><td style="vertical-align:top"><p>44.2%*</p></td><td style="vertical-align:top"><p>40.8%*</p></td></tr><tr><td style="vertical-align:top"><p>Hot&nbsp;flushes</p></td><td style="vertical-align:top"><p>37.7%</p></td><td style="vertical-align:top"><p>41.7%**</p></td><td style="vertical-align:top"><p>43.9%**</p></td></tr><tr><td style="vertical-align:top"><p>Vaginal&nbsp;bleeding</p></td><td style="vertical-align:top"><p>6.3%</p></td><td style="vertical-align:top"><p>9.6%**</p></td><td style="vertical-align:top"><p>12.7%**</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Significantly&nbsp;less&nbsp;than&nbsp;with&nbsp;letrozole&nbsp;monotherapy</p><p>**&nbsp;&nbsp;&nbsp;&nbsp;Significantly&nbsp;more than with&nbsp;letrozole&nbsp;monotherapy</p><p>Note&nbsp;:&nbsp;Reporting&nbsp;period&nbsp;is&nbsp;during&nbsp;treatment&nbsp;or&nbsp;within&nbsp;30&nbsp;days&nbsp;of&nbsp;stopping&nbsp;treatment</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description&nbsp;of&nbsp;selected&nbsp;adverse&nbsp;reactions</u></p><p><u><em>Cardiac&nbsp;adverse&nbsp;reactions</em></u></p><p>In&nbsp;the&nbsp;adjuvant&nbsp;setting,&nbsp;in&nbsp;addition&nbsp;to&nbsp;the&nbsp;date&nbsp;presented&nbsp;in&nbsp;Table&nbsp;2,&nbsp;the&nbsp;following&nbsp;adverse&nbsp;events&nbsp;were reported&nbsp;forletrozole&nbsp;and&nbsp;tamoxifen,&nbsp;respectively&nbsp;(at&nbsp;median&nbsp;treatment&nbsp;duration&nbsp;of&nbsp;60&nbsp;months&nbsp;plus&nbsp;30 days):&nbsp;angina&nbsp;requiringsurgery&nbsp;(1.0%&nbsp;vs.&nbsp;1.0%);&nbsp;cardiac&nbsp;failure&nbsp;(1.1%&nbsp;vs.&nbsp;0.6%);&nbsp;hypertension&nbsp;(5.6%&nbsp;vs.&nbsp;5.7%);&nbsp;cerebrovascular&nbsp;accident/transient&nbsp;ischaemic&nbsp;attack&nbsp;(2.1%&nbsp;vs.&nbsp;1.9%).</p><p>In the extended&nbsp;adjuvant setting&nbsp;for letrozole&nbsp;(median duration of treatment 5 years) and placebo (median&nbsp;duration&nbsp;oftreatment&nbsp;3&nbsp;years),&nbsp;respectively:&nbsp;angina&nbsp;requiring&nbsp;surgery&nbsp;(0.8%&nbsp;vs.&nbsp;0.6%);&nbsp;new&nbsp;or worsening&nbsp;angina (1.4% vs. 1.0%); myocardial infarction (1.0% vs. 0.7%); thromboembolic&nbsp;event*&nbsp;(0.9%&nbsp;vs.&nbsp;0.3%);&nbsp;stroke/transient&nbsp;ischaemic&nbsp;attack*&nbsp;(1.5%&nbsp;vs.&nbsp;0.8%)&nbsp;were&nbsp;reported. Events&nbsp;marked&nbsp;*were&nbsp;statistically&nbsp;significantly&nbsp;different&nbsp;in&nbsp;the&nbsp;two&nbsp;treatment&nbsp;arms.</p><p>&nbsp;</p><p><u><em>Skeletal&nbsp;adverse&nbsp;reactions</em></u></p><p>For&nbsp;skeletal&nbsp;safety&nbsp;data&nbsp;from&nbsp;the&nbsp;adjuvant&nbsp;setting,&nbsp;please&nbsp;refer&nbsp;to&nbsp;Table&nbsp;2.</p><p>In the extended&nbsp;adjuvant setting, significantly&nbsp;more patients&nbsp;treated with letrozole&nbsp;experienced bone fractures&nbsp;orosteoporosis&nbsp;(bone&nbsp;fractures,&nbsp;10.4%&nbsp;and&nbsp;osteoporosis,&nbsp;12.2%)&nbsp;than&nbsp;patients&nbsp;in&nbsp;the&nbsp;placebo arm&nbsp;(5.8%&nbsp;and&nbsp;6.4%,respectively).&nbsp;Median&nbsp;duration&nbsp;of&nbsp;treatment&nbsp;was&nbsp;5&nbsp;years&nbsp;for&nbsp;letrozole,&nbsp;compared with 3 years for placebo.</p><p>&nbsp;</p><p><u>Reporting&nbsp;of&nbsp;suspected&nbsp;adverse&nbsp;reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals&nbsp;are&nbsp;asked&nbsp;to&nbsp;report&nbsp;anysuspected&nbsp;adverse&nbsp;reactions&nbsp;via&nbsp;the&nbsp;National&nbsp;Pharmacovigilance and Drug Safety&nbsp;Centre (NPC) +966-11-2038222. Exts: 2317-2356-2353-2354-2334-2340. Toll free phone: 8002490000. E-mail:&nbsp;npc.drug@sfda.gov.sa.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Isolated&nbsp;cases&nbsp;of&nbsp;overdosage&nbsp;with&nbsp;letrozole have&nbsp;been&nbsp;reported.</p><p>No&nbsp;specific&nbsp;treatment&nbsp;for&nbsp;overdosage&nbsp;is&nbsp;known;&nbsp;treatment&nbsp;should&nbsp;be&nbsp;symptomatic&nbsp;and&nbsp;supportive.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic&nbsp;group:&nbsp;Endocrine&nbsp;therapy.&nbsp;Hormone&nbsp;antagonist&nbsp;and&nbsp;related&nbsp;agents:&nbsp;aromatase inhibitor, ATC code: L02BG04.</p><p>&nbsp;</p><p><u>Pharmacodynamic&nbsp;effects</u></p><p>The elimination of oestrogen-mediated growth stimulation is a prerequisite for tumour response in cases&nbsp;where&nbsp;thegrowth&nbsp;of&nbsp;tumour&nbsp;tissue&nbsp;depends&nbsp;on&nbsp;the&nbsp;presence&nbsp;of&nbsp;oestrogens&nbsp;and&nbsp;endocrine&nbsp;therapy is used. In postmenopausal women, oestrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens -primarily&nbsp;androstenedione and testosterone -&nbsp;to oestrone and oestradiol. The suppression of oestrogen biosynthesis in peripheral tissues and the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme.</p><p>&nbsp;</p><p>Letrozole&nbsp;is&nbsp;a&nbsp;non-steroidal&nbsp;aromatase&nbsp;inhibitor.&nbsp;It&nbsp;inhibits&nbsp;the&nbsp;aromatase&nbsp;enzyme&nbsp;by&nbsp;competitively binding to the haem of the aromatase cytochrome P450, resulting in a reduction of oestrogen biosynthesis in all tissues where present.</p><p>&nbsp;</p><p>In&nbsp;healthy&nbsp;postmenopausal&nbsp;women,&nbsp;single&nbsp;doses&nbsp;of&nbsp;0.1&nbsp;mg,&nbsp;0.5 mg,&nbsp;and&nbsp;2.5&nbsp;mg&nbsp;letrozole&nbsp;suppress serum oestrone and oestradiol by 75%-78% and 78% from baseline respectively. Maximum suppression is achieved in 48-78 hours.</p><p>&nbsp;</p><p>In postmenopausal patients with advanced breast cancer, daily doses of 0.1 mg to 5 mg suppressed plasma concentration of oestradiol, oestrone, and oestrone sulphate by 75-95% from baseline in all patients&nbsp;treated.&nbsp;Withdoses&nbsp;of&nbsp;0.5&nbsp;mg&nbsp;and&nbsp;higher,&nbsp;many&nbsp;values&nbsp;of&nbsp;oestrone&nbsp;and&nbsp;oestrone&nbsp;sulphate were below the limit of detection in the assays, indicating that higher oestrogen suppression is achieved with these doses. Oestrogen suppression was maintained throughout treatment in all these patients.</p><p>&nbsp;</p><p>Letrozole&nbsp;is&nbsp;highly&nbsp;specific&nbsp;in&nbsp;inhibiting&nbsp;aromatase&nbsp;activity.&nbsp;Impairment&nbsp;of&nbsp;adrenal&nbsp;steroidogenesis&nbsp;has not been observed. No&nbsp;clinically&nbsp;relevant changes were&nbsp;found&nbsp;in&nbsp;the plasma concentrations of cortisol, aldosterone, 11-deoxycortisol, 17-hydroxyprogesterone, and ACTH or&nbsp;in plasma renin activity&nbsp;among postmenopausal patients treated with&nbsp;a daily&nbsp;dose of letrozole 0.1 mg to 5 mg. The ACTH stimulation test performed after 6 and 12 weeks of treatment with daily doses of 0.1 mg, 0.25 mg, 0.5 mg, 1 mg, 2,5 mg and 5 mg did not indicate any attenuation of aldosterone or cortisol production. Thus, glucocorticoid and mineralocorticoid supplementation is not necessary.</p><p>No changes were noted in plasma concentrations of androgens (androstenedione and testosterone) among&nbsp;healthypostmenopausal&nbsp;women&nbsp;after&nbsp;0.1 mg,&nbsp;0.5&nbsp;mg,&nbsp;and&nbsp;2.5&nbsp;mg&nbsp;single&nbsp;doses&nbsp;of&nbsp;letrozole&nbsp;or&nbsp;in plasma concentrations of androstenedione among postmenopausal patients treated with daily doses of&nbsp;0.1 mg to 5 mg, indicating that the blockade of oestrogen biosynthesis does not lead to accumulation of&nbsp;androgenicprecursors.&nbsp;Plasma&nbsp;levels&nbsp;of&nbsp;LH&nbsp;and&nbsp;FSH&nbsp;are&nbsp;not&nbsp;affected&nbsp;by&nbsp;letrozole&nbsp;in&nbsp;patients,&nbsp;nor&nbsp;is thyroid function as evaluated by TSH, T4, and T3 uptake test.</p><p><u>Adjuvant&nbsp;treatment</u></p><p><em><u>Study&nbsp;BIG&nbsp;1-98</u></em></p><p>BIG&nbsp;1-98&nbsp;was&nbsp;a multicentre,&nbsp;double-blind&nbsp;study&nbsp;in which&nbsp;over&nbsp;8,000&nbsp;postmenopausal&nbsp;women&nbsp;with hormonereceptor-positive&nbsp;early&nbsp;breast&nbsp;cancer&nbsp;were&nbsp;randomised&nbsp;to&nbsp;one&nbsp;of&nbsp;the&nbsp;following&nbsp;treatments:</p><p>A.&nbsp;tamoxifen&nbsp;for&nbsp;5&nbsp;years;&nbsp;B.&nbsp;letrozole&nbsp;for&nbsp;5&nbsp;years;&nbsp;C.&nbsp;tamoxifen&nbsp;for&nbsp;2&nbsp;years&nbsp;followed&nbsp;by&nbsp;letrozole&nbsp;for&nbsp;3 years; D. letrozole for 2 years followed by tamoxifen for 3 years.</p><p>The primary endpoint was disease-free survival (DFS); secondary efficacy endpoints were time to distant metastasis (TDM), distant disease-free survival (DDFS), overall survival (OS), systemic disease-free&nbsp;survival&nbsp;(SDFS),&nbsp;invasivecontralateral&nbsp;breast&nbsp;cancer&nbsp;and&nbsp;time&nbsp;to&nbsp;breast&nbsp;cancer&nbsp;recurrence.</p><p>&nbsp;</p><p><em>Efficacy&nbsp;results&nbsp;at&nbsp;a&nbsp;median&nbsp;follow-up&nbsp;of&nbsp;26&nbsp;and&nbsp;60&nbsp;months</em></p><p>Data in Table 4 reflect the results of the Primary Core Analysis&nbsp;(PCA) based on data from&nbsp;the monotherapy&nbsp;arms (A and B) and from the two switching&nbsp;arms (C and D) at a median treatment duration&nbsp;of&nbsp;24&nbsp;months&nbsp;and&nbsp;a&nbsp;medianfollow-up&nbsp;of&nbsp;26&nbsp;months&nbsp;and&nbsp;at&nbsp;a&nbsp;median&nbsp;treatment&nbsp;duration&nbsp;of&nbsp;32 months and a median follow-up of 60 months.</p><p>The&nbsp;5-year&nbsp;DFS&nbsp;rates&nbsp;were&nbsp;84%&nbsp;for&nbsp;letrozole&nbsp;and&nbsp;81.4%&nbsp;for&nbsp;tamoxifen.</p><p>&nbsp;</p><p><u><strong>Table 4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Primary&nbsp;Core&nbsp;Analysis:&nbsp;Disease-free&nbsp;and&nbsp;overall&nbsp;survival,at&nbsp;a&nbsp;median&nbsp;follow-up&nbsp;of&nbsp;26&nbsp;months and at median follow-up of 60 months (ITT population)</strong></u></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong>Primary&nbsp;Core&nbsp;Analysis</strong></p><p><strong>Median&nbsp;follow-up&nbsp;26&nbsp;months&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Median&nbsp;follow-up&nbsp;60&nbsp;months</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Letrozole N=4003</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen N=4007</strong></p></td><td style="vertical-align:top"><p><strong>HR<sup>1</sup>(95%&nbsp;CI)</strong></p><p><strong><em>P</em></strong></p></td><td style="vertical-align:top"><p><strong>Letrozole N=4003</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen N=4007</strong></p></td><td style="vertical-align:top"><p><strong>HR1<sup>1</sup>(95%&nbsp;CI)</strong></p><p><strong>P</strong></p></td></tr><tr><td style="vertical-align:top"><p>Disease-free&nbsp;survival</p><p>(primary) &ndash; events&nbsp;(protocol&nbsp;definition<sup>2</sup>)</p></td><td style="vertical-align:top"><p>351</p></td><td style="vertical-align:top"><p>428</p></td><td style="vertical-align:top"><p>0.81</p><p>(0.70,0.93)</p><p>0.003</p></td><td style="vertical-align:top"><p>585</p></td><td style="vertical-align:top"><p>664</p></td><td style="vertical-align:top"><p>0.86</p><p>(0.77,0.96)</p><p>0.008</p></td></tr><tr><td style="vertical-align:top"><p>Overall&nbsp;survival</p><p>(secondary)Number&nbsp;of&nbsp;deaths</p></td><td style="vertical-align:top"><p>166</p></td><td style="vertical-align:top"><p>192</p></td><td style="vertical-align:top"><p>0.86</p><p>(0.70,1.06)</p></td><td style="vertical-align:top"><p>330</p></td><td style="vertical-align:top"><p>374</p></td><td style="vertical-align:top"><p>0.87</p><p>(0.75,1.01)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table><p>HR&nbsp;=&nbsp;Hazard&nbsp;ratio;&nbsp;CI&nbsp;=&nbsp;Confidence&nbsp;interval</p><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Log&nbsp;rank&nbsp;test,&nbsp;stratified&nbsp;by&nbsp;randomisation&nbsp;option&nbsp;and&nbsp;use&nbsp;of&nbsp;chemotherapy&nbsp;(yes/no)</p><p><sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DFS&nbsp;events:&nbsp;loco-regional&nbsp;recurrence,&nbsp;distant&nbsp;metastasis,&nbsp;invasive&nbsp;contralateral&nbsp;breast&nbsp;cancer,&nbsp;second (non-breast) primary malignancy, death from any cause without a prior cancer&nbsp;event.</p><p>&nbsp;</p><p><em>Results&nbsp;at&nbsp;a&nbsp;median&nbsp;follow-up&nbsp;of&nbsp;73&nbsp;months&nbsp;(monotherapy&nbsp;arms&nbsp;only)</em></p><p>The&nbsp;Monotherapy&nbsp;Arms&nbsp;Analysis&nbsp;(MAA)&nbsp;long-term&nbsp;update&nbsp;of the&nbsp;efficacy&nbsp;of letrozole&nbsp;monotherapy compared&nbsp;totamoxifen&nbsp;monotherapy&nbsp;(median&nbsp;duration&nbsp;of&nbsp;adjuvant&nbsp;treatment:&nbsp;5&nbsp;years)&nbsp;is&nbsp;presented&nbsp;in Table 5.</p><p><strong><u>Table 5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Monotherapy&nbsp;Arms&nbsp;Analysis:&nbsp;Disease-free&nbsp;and&nbsp;overall&nbsp;survival&nbsp;at&nbsp;a&nbsp;median&nbsp;follow-&nbsp;up of&nbsp;73 months (ITT population)</u></strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Letrozole</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen N=2459</strong></p></td><td style="vertical-align:top"><p><strong>HazardRatio<sup>1</sup>&nbsp;(95% CI)</strong></p></td><td style="vertical-align:top"><p><strong><em>P&nbsp;</em>Value</strong></p></td></tr><tr><td style="vertical-align:top"><p>Disease-free&nbsp;survival&nbsp;events&nbsp;(primary<sup>)2</sup></p></td><td style="vertical-align:top"><p>509</p></td><td style="vertical-align:top"><p>565</p></td><td style="vertical-align:top"><p>0.88&nbsp;(0.78,&nbsp;0.99)</p></td><td style="vertical-align:top"><p>0.03</p></td></tr><tr><td style="vertical-align:top"><p>Time&nbsp;to&nbsp;distant&nbsp;metastasis&nbsp;(secondary)</p></td><td style="vertical-align:top"><p>257</p></td><td style="vertical-align:top"><p>298</p></td><td style="vertical-align:top"><p>0.85&nbsp;(0.72,&nbsp;1.00)</p></td><td style="vertical-align:top"><p>0.045</p></td></tr><tr><td style="vertical-align:top"><p>Overall&nbsp;survival&nbsp;(secondary)&nbsp;-&nbsp;deaths</p></td><td style="vertical-align:top"><p>303</p></td><td style="vertical-align:top"><p>343</p></td><td style="vertical-align:top"><p>0.87&nbsp;(0.75,&nbsp;1.02)</p></td><td style="vertical-align:top"><p>0.08</p></td></tr><tr><td style="vertical-align:top"><p>Censored&nbsp;analysis&nbsp;of&nbsp;DFS<sup>3</sup></p></td><td style="vertical-align:top"><p>509</p></td><td style="vertical-align:top"><p>543</p></td><td style="vertical-align:top"><p>0.85&nbsp;(0.75,&nbsp;0.96)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Censored&nbsp;analysis&nbsp;of&nbsp;OS<sup>3</sup></p></td><td style="vertical-align:top"><p>303</p></td><td style="vertical-align:top"><p>338</p></td><td style="vertical-align:top"><p>0.82&nbsp;(0.70,&nbsp;0.96)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Log&nbsp;rank&nbsp;test,&nbsp;stratified&nbsp;by&nbsp;randomisation&nbsp;option&nbsp;and&nbsp;use&nbsp;of&nbsp;chemotherapy&nbsp;(yes/no)</p><p><sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DFS&nbsp;events:&nbsp;loco-regional&nbsp;recurrence,&nbsp;distant&nbsp;metastasis,&nbsp;invasive&nbsp;contralateral&nbsp;breast&nbsp;cancer, second&nbsp;(non-breast)&nbsp;primary&nbsp;malignancy,&nbsp;death&nbsp;from&nbsp;any&nbsp;cause without&nbsp;a prior&nbsp;cancer&nbsp;event.</p><p><sup>3</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Observations&nbsp;in&nbsp;the&nbsp;tamoxifen&nbsp;arm&nbsp;censored&nbsp;at&nbsp;the&nbsp;date&nbsp;of&nbsp;selectively&nbsp;switching&nbsp;to&nbsp;letrozole<sup>3</sup></p><p>&nbsp;</p><p>&nbsp;</p><p><em>Sequential&nbsp;Treatments&nbsp;Analysis&nbsp;(STA)</em></p><p>The&nbsp;Sequential&nbsp;Treatments&nbsp;Analysis&nbsp;(STA)&nbsp;addresses&nbsp;the&nbsp;second&nbsp;primary&nbsp;question&nbsp;of&nbsp;BIG&nbsp;1-98,&nbsp;namely whether sequencing&nbsp;of tamoxifen and letrozole would be superior to monotherapy.&nbsp;There were no significant differences in DFS, OS, SDFS, or DDFS from switch with respect to monotherapy</p><p>(Table&nbsp;6).</p><p><strong><u>Table 6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sequential&nbsp;treatments&nbsp;analysis&nbsp;of&nbsp;disease-free&nbsp;survival&nbsp;with&nbsp;letrozole&nbsp;as&nbsp;initial endocrine agent (STA switch population)</u></strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Number&nbsp;of&nbsp;events<sup>1</sup></strong></p></td><td style="vertical-align:top"><p><strong>Hazard&nbsp;ratio<sup>2</sup></strong></p></td><td style="vertical-align:top"><p><strong>(97.5%</strong></p><p><strong>confidence interval)</strong></p></td><td style="vertical-align:top"><p><strong>Cox&nbsp;model</strong></p><p><strong><em>P</em>-&nbsp;value</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>[Letrozole&nbsp;&rarr;]Tamoxifen</strong></p></td><td style="vertical-align:top"><p>1460</p></td><td style="vertical-align:top"><p>160</p></td><td style="vertical-align:top"><p>0.92</p></td><td style="vertical-align:top"><p>(0.72,&nbsp;1.17)</p></td><td style="vertical-align:top"><p>0.42</p></td></tr><tr><td style="vertical-align:top"><p><strong>Letrozole</strong></p></td><td style="vertical-align:top"><p>1463</p></td><td style="vertical-align:top"><p>178</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protocol&nbsp;definition,&nbsp;including&nbsp;second&nbsp;non-breast&nbsp;primary&nbsp;malignancies,&nbsp;after&nbsp;switch&nbsp;/&nbsp;beyond&nbsp;two&nbsp;years</p><p><sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted&nbsp;by&nbsp;chemotherapy&nbsp;use</p><p>&nbsp;</p><p>There&nbsp;were&nbsp;no&nbsp;significant&nbsp;differences&nbsp;in&nbsp;DFS,&nbsp;OS,&nbsp;SDFS&nbsp;or&nbsp;DDFS&nbsp;in&nbsp;any&nbsp;of&nbsp;the&nbsp;STA&nbsp;from randomisation pairwise comparisons (Table 7).</p><p>&nbsp;</p><p><u><strong>Table 7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sequential&nbsp;Treatments&nbsp;Analyses&nbsp;from&nbsp;randomisation&nbsp;(STA-R)&nbsp;of&nbsp;disease-free&nbsp;survival&nbsp;(ITT STA-R population)</strong></u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Letrozole&nbsp;&rarr;&nbsp;Tamoxifen</strong></p></td><td style="vertical-align:top"><p><strong>Letrozole</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Number&nbsp;of&nbsp;patients</p><p>Number&nbsp;of&nbsp;patients&nbsp;with&nbsp;DFS&nbsp;events&nbsp;(protocol&nbsp;definition) Hazard ratio<sup>1</sup>&nbsp;(99% CI)</p></td><td style="vertical-align:top"><p>1540</p><p>236</p></td><td style="vertical-align:top"><p>1546</p><p>248</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>0.96&nbsp;(0.76,&nbsp;1.21)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Letrozole&nbsp;&rarr;&nbsp;Tamoxifen</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen<sup>2</sup></strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Number&nbsp;of&nbsp;patients</p><p>Number&nbsp;of&nbsp;patients&nbsp;with&nbsp;DFS&nbsp;events&nbsp;(protocol&nbsp;definition) Hazard ratio<sup>1</sup>&nbsp;(99% CI)</p></td><td style="vertical-align:top"><p>1540</p><p>236</p></td><td style="vertical-align:top"><p>1548</p><p>269</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>0.87&nbsp;(0.69,&nbsp;1.09)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted&nbsp;by&nbsp;chemotherapy&nbsp;use&nbsp;(yes/no)</p><p><sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;624&nbsp;(40%)&nbsp;patients&nbsp;selectively&nbsp;crossed&nbsp;to&nbsp;letrozole&nbsp;after&nbsp;tamoxifen&nbsp;arm&nbsp;unblinded&nbsp;in&nbsp;2005</p></td></tr></tbody></table><p><em><u>Study&nbsp;D2407</u></em></p><p>Study&nbsp;D2407&nbsp;is&nbsp;an&nbsp;open-label,&nbsp;randomised,&nbsp;multicentre&nbsp;post&nbsp;approval&nbsp;safety&nbsp;study&nbsp;designed&nbsp;to&nbsp;compare the effects of adjuvant treatment with letrozole&nbsp;and tamoxifen on bone mineral density (BMD) and serum lipid profiles. A total of 262 patients&nbsp;were assigned&nbsp;either letrozole&nbsp;for 5 years or tamoxifen&nbsp;for 2 years followed by letrozole for 3 years.</p><p>&nbsp;</p><p>At 24 months&nbsp;there&nbsp;was&nbsp;a statistically&nbsp;significant&nbsp;difference&nbsp;in the primary&nbsp;end-point;&nbsp;the&nbsp;lumbar&nbsp;spine BMD&nbsp;(L2-L4)showed&nbsp;a&nbsp;median&nbsp;decrease&nbsp;of&nbsp;4.1%&nbsp;for&nbsp;letrozole&nbsp;compared&nbsp;to&nbsp;a&nbsp;median&nbsp;increase&nbsp;of&nbsp;0.3% for tamoxifen.</p><p>&nbsp;</p><p>No&nbsp;patient&nbsp;with&nbsp;a&nbsp;normal&nbsp;BMD&nbsp;at&nbsp;baseline&nbsp;became&nbsp;osteoporotic&nbsp;during&nbsp;2&nbsp;years&nbsp;of&nbsp;treatment&nbsp;and&nbsp;only 1 patient with osteopenia&nbsp;at baseline (T score of -1.9) developed&nbsp;osteoporosis&nbsp;during&nbsp;the treatment period (assessment by central review).</p><p>&nbsp;</p><p>The&nbsp;results&nbsp;for&nbsp;total&nbsp;hip&nbsp;BMD&nbsp;were&nbsp;similar&nbsp;to&nbsp;those&nbsp;for&nbsp;lumbar&nbsp;spine&nbsp;but&nbsp;less&nbsp;pronounced.</p><p>There&nbsp;was&nbsp;no&nbsp;significant&nbsp;difference&nbsp;between&nbsp;treatments&nbsp;in&nbsp;the&nbsp;rate&nbsp;of&nbsp;fractures&nbsp;&ndash;&nbsp;15%&nbsp;in&nbsp;the&nbsp;letrozole arm, 17% in the tamoxifen arm.</p><p>&nbsp;</p><p>Median&nbsp;total cholesterol&nbsp;levels&nbsp;in the&nbsp;tamoxifen&nbsp;arm&nbsp;were decreased&nbsp;by 16% after 6 months&nbsp;compared to&nbsp;baselineand&nbsp;this&nbsp;decrease&nbsp;was&nbsp;maintained&nbsp;at&nbsp;subsequent&nbsp;visits&nbsp;up&nbsp;to&nbsp;24&nbsp;months.&nbsp;In&nbsp;the&nbsp;letrozole&nbsp;arm, total cholesterol&nbsp;levels were relatively stable over time, giving a statistically significant difference&nbsp;in favor of tamoxifen at each time point.</p><p>&nbsp;</p><p><em><u>Extended&nbsp;adjuvant&nbsp;treatment&nbsp;(MA-17)</u></em></p><p>In a multicentre, double-blind, randomised, placebo-controlled&nbsp;study (MA-17), over 5,100 postmenopausal&nbsp;womenwith&nbsp;receptor-positive&nbsp;or&nbsp;unknown&nbsp;primary&nbsp;breast&nbsp;cancer&nbsp;who&nbsp;had&nbsp;completed adjuvant&nbsp;treatment&nbsp;with tamoxifen&nbsp;(4.5to&nbsp;6 years) were&nbsp;randomised&nbsp;to either letrozole or placebo&nbsp;for 5 years.</p><p>&nbsp;</p><p>The&nbsp;primary&nbsp;endpoint&nbsp;was&nbsp;disease-free&nbsp;survival,&nbsp;defined&nbsp;as&nbsp;the&nbsp;interval&nbsp;between&nbsp;randomisation&nbsp;and&nbsp;the earliest occurrence of loco-regional recurrence, distant metastasis, or contralateral breast cancer.</p><p>&nbsp;</p><p>The&nbsp;first&nbsp;planned&nbsp;interim&nbsp;analysis&nbsp;at&nbsp;a&nbsp;median&nbsp;follow-up&nbsp;of&nbsp;around&nbsp;28&nbsp;months&nbsp;(25%&nbsp;of&nbsp;patients&nbsp;being followed&nbsp;up for at least 38 months), showed that letrozole significantly&nbsp;reduced the risk of breast cancer recurrence by 42% compared with placebo (HR 0.58; 95% CI 0.45, 0.76;&nbsp;<em>P</em>=0.00003).&nbsp;The benefit in favour of letrozole was observedregardless of nodal status. There was no significant difference in overall survival: (letrozole 51 deaths; placebo 62; HR 0.82; 95% CI 0.56, 1.19).</p><p>&nbsp;</p><p>Consequently,&nbsp;after the the first interim&nbsp;analysis the study was unblinded and continued&nbsp;in an open- label fashion&nbsp;andpatients&nbsp;in&nbsp;the&nbsp;placebo&nbsp;arm&nbsp;were&nbsp;allowed&nbsp;to&nbsp;switch&nbsp;to&nbsp;letrozole for&nbsp;up&nbsp;to&nbsp;5&nbsp;years.&nbsp;Over 60% of eligible patients (disease-free&nbsp;at unblinding) opted to switch to letrozole.&nbsp;The final analysis included&nbsp;1,551 women who switched&nbsp;fromplacebo to letrozole at a median of 31 months (range 12 to 106&nbsp;months)&nbsp;after&nbsp;completion&nbsp;of&nbsp;tamoxifen&nbsp;adjuvanttherapy.&nbsp;Median&nbsp;duration&nbsp;for&nbsp;letrozole&nbsp;after&nbsp;switch was 40 months.</p><p>&nbsp;</p><p>The&nbsp;final&nbsp;analysis&nbsp;conducted&nbsp;at&nbsp;a&nbsp;median&nbsp;follow-up&nbsp;of&nbsp;62&nbsp;months&nbsp;confirmed&nbsp;the&nbsp;significant&nbsp;reduction in the risk of breast cancer recurrence with letrozole.</p><p><strong><u>&nbsp;Table&nbsp;8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disease-free&nbsp;and&nbsp;overall&nbsp;survival&nbsp;(Modified&nbsp;ITT&nbsp;population)</u></strong></p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Median&nbsp;follow-up&nbsp;28&nbsp;months&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Median&nbsp;follow-up&nbsp;62&nbsp;months</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Letrozole</p><p>N=2582</p></td><td style="vertical-align:top"><p>Placebo</p><p>N=2586</p></td><td style="vertical-align:top"><p>HR&nbsp;(95%&nbsp;CI)&nbsp;<sup>2</sup></p></td><td style="vertical-align:top"><p>Letrozole N=2582</p></td><td style="vertical-align:top"><p>Placebo N=2586</p></td><td style="vertical-align:top"><p>HR&nbsp;(95%&nbsp;CI)&nbsp;<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>P&nbsp;</em>value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>P&nbsp;</em>value</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Disease-free&nbsp;survival</strong><sup>3</sup></p></td></tr><tr><td style="vertical-align:top"><p>Events</p></td><td style="vertical-align:top"><p>92&nbsp;(3.6%)</p></td><td style="vertical-align:top"><p>155&nbsp;(6.0%)</p></td><td style="vertical-align:top"><p>0.58</p></td><td style="vertical-align:top"><p>209</p></td><td style="vertical-align:top"><p>286</p></td><td style="vertical-align:top"><p>0.75</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.45,&nbsp;0.76)</p></td><td style="vertical-align:top"><p>(8.1%)</p></td><td style="vertical-align:top"><p>(11.1%)</p></td><td style="vertical-align:top"><p>(0.63,&nbsp;0.89)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.00003</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>4-year&nbsp;DFS&nbsp;rate</p></td><td style="vertical-align:top"><p>94.4%</p></td><td style="vertical-align:top"><p>89.8%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>94.4%</p></td><td style="vertical-align:top"><p>91.4%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Disease-free&nbsp;survival</strong><sup>3</sup><strong>,&nbsp;including&nbsp;deaths&nbsp;from&nbsp;any&nbsp;cause</strong></p></td></tr><tr><td style="vertical-align:top"><p>Events</p></td><td style="vertical-align:top"><p>122&nbsp;(4.7%)</p></td><td style="vertical-align:top"><p>193&nbsp;(7.5%)</p></td><td style="vertical-align:top"><p>0.62</p></td><td style="vertical-align:top"><p>344</p></td><td style="vertical-align:top"><p>402</p></td><td style="vertical-align:top"><p>0.89</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.49,&nbsp;0.78)</p></td><td style="vertical-align:top"><p>(13.3%)</p></td><td style="vertical-align:top"><p>(15.5%)</p></td><td style="vertical-align:top"><p>(0.77,&nbsp;1.03)</p></td></tr><tr><td style="vertical-align:top"><p>5-year&nbsp;DFS&nbsp;rate</p></td><td style="vertical-align:top"><p>90.5%</p></td><td style="vertical-align:top"><p>80.8%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>88.8%</p></td><td style="vertical-align:top"><p>86.7%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Distant&nbsp;metastases</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Events</p></td><td style="vertical-align:top"><p>57&nbsp;(2.2%)</p></td><td style="vertical-align:top"><p>93&nbsp;(3.6%)</p></td><td style="vertical-align:top"><p>0.61</p></td><td style="vertical-align:top"><p>142</p></td><td style="vertical-align:top"><p>169</p></td><td style="vertical-align:top"><p>0.88</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.44,&nbsp;0.84)</p></td><td style="vertical-align:top"><p>(5.5%)</p></td><td style="vertical-align:top"><p>(6.5%)</p></td><td style="vertical-align:top"><p>(0.70,&nbsp;1.10)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall&nbsp;survival</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Deaths</p></td><td style="vertical-align:top"><p>51&nbsp;(2.0%)</p></td><td style="vertical-align:top"><p>62&nbsp;(2.4%)</p></td><td style="vertical-align:top"><p>0.82</p></td><td style="vertical-align:top"><p>236&nbsp;(9.1%)</p></td><td style="vertical-align:top"><p>232&nbsp;(9.0%)</p></td><td style="vertical-align:top"><p>1.13</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.56,&nbsp;1.19)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.95,&nbsp;1.36)</p></td></tr><tr><td style="vertical-align:top"><p>Deaths<sup>4</sup></p></td><td style="vertical-align:top"><p>-&nbsp;-</p></td><td style="vertical-align:top"><p>-&nbsp;-</p></td><td style="vertical-align:top"><p>-&nbsp;-</p></td><td style="vertical-align:top"><p>236<sup>5</sup></p></td><td style="vertical-align:top"><p>170<sup>6</sup></p></td><td style="vertical-align:top"><p>0.78</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(9.1%)</p></td><td style="vertical-align:top"><p>(6.6%)</p></td><td style="vertical-align:top"><p>(0.64,&nbsp;0.96)</p></td></tr></tbody></table><p>HR&nbsp;=&nbsp;Hazard&nbsp;ratio;&nbsp;CI&nbsp;=&nbsp;Confidence&nbsp;Interval</p><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When the study was unblinded in 2003, 1551 patients in the randomised placebo arm (60% of those&nbsp;eligible&nbsp;toswitch,&nbsp;i.e.&nbsp;who&nbsp;were&nbsp;disease-free)&nbsp;switched&nbsp;to&nbsp;letrozole&nbsp;at&nbsp;a&nbsp;median&nbsp;31&nbsp;months after randomisation.&nbsp;The analyses presented here ignore the selective crossover.</p><p><sup>2.</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stratified&nbsp;by&nbsp;receptor&nbsp;status,&nbsp;nodal&nbsp;status&nbsp;and&nbsp;prior&nbsp;adjuvant&nbsp;chemotherapy.</p><p><sup>3.</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protocol&nbsp;definition&nbsp;of&nbsp;disease-free&nbsp;survival&nbsp;events:&nbsp;loco-regional&nbsp;recurrence,&nbsp;distant&nbsp;metastasis&nbsp;or contralateral breast cancer.</p><p><sup>4.</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exploratory&nbsp;analysis,&nbsp;censoring&nbsp;follow-up&nbsp;times&nbsp;at&nbsp;the&nbsp;date&nbsp;of&nbsp;switch&nbsp;(if&nbsp;it&nbsp;occurred)&nbsp;in&nbsp;the placebo arm.</p><p><sup>5.</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Median&nbsp;follow-up&nbsp;62&nbsp;months.<br /><sup>6.</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Median&nbsp;follow-up&nbsp;until&nbsp;switch&nbsp;(if&nbsp;it&nbsp;occurred)&nbsp;37&nbsp;months.</p><p>&nbsp;</p><p>In the MA-17 bone substudy in which concomitant&nbsp;calcium&nbsp;and vitamin D were given, greater decreases&nbsp;in&nbsp;BMDcompared&nbsp;to&nbsp;baseline&nbsp;occurred&nbsp;with&nbsp;letrozole&nbsp;compared&nbsp;with&nbsp;placebo.&nbsp;The&nbsp;only statistically significant&nbsp;differenceoccurred&nbsp;at 2&nbsp;years&nbsp;and&nbsp;was&nbsp;in&nbsp;total&nbsp;hip&nbsp;BMD&nbsp;(letrozole&nbsp;median decrease of 3.8% vs placebo median decrease of 2.0%).</p><p>In&nbsp;the&nbsp;MA-17&nbsp;lipid&nbsp;substudy&nbsp;there&nbsp;were&nbsp;no&nbsp;significant&nbsp;differences&nbsp;between&nbsp;letrozole&nbsp;and&nbsp;placebo&nbsp;in&nbsp;total cholesterol or in any lipid fraction.</p><p>&nbsp;</p><p>In the updated quality&nbsp;of life substudy&nbsp;there were no significant differences&nbsp;between treatments in physical component&nbsp;summary&nbsp;score or mental component summary&nbsp;score, or in any domain score in the SF-36 scale. In the MENQOL&nbsp;scale, significantly&nbsp;more women in the letrozole arm&nbsp;than in the placebo arm were most bothered(generally&nbsp;in the first year of treatment) by those symptoms&nbsp;deriving from&nbsp;oestrogen&nbsp;deprivation&nbsp;&ndash;&nbsp;hot&nbsp;flushes&nbsp;andvaginal&nbsp;dryness.&nbsp;The&nbsp;symptom&nbsp;that&nbsp;bothered&nbsp;most&nbsp;patients in both treatment arms was aching muscles, with a statistically significant difference in favour of&nbsp;placebo.</p><p><em><u>Neoadjuvant&nbsp;treatment</u></em></p><p>A double blind trial (P024)&nbsp;was conducted in 337 postmenopausal&nbsp;breast cancer patients randomly allocated either letrozole 2.5 mg for 4 months or tamoxifen&nbsp;for 4 months. At baseline all patientshad tumours stage T2-T4c, N0-2, M0, ER and/or PgR positive and none of the patients would have qualified for breast-conserving&nbsp;surgery. Based on clinical assessment there were 55% objective responses in the letrozole arm versus 36% for the tamoxifen arm (<em>P</em>&lt;0.001).&nbsp;This finding was consistently confirmed by ultrasound (letrozole 35% vs tamoxifen 25%,&nbsp;<em>P</em>=0.04) and mammography (letrozole&nbsp;34%&nbsp;vs&nbsp;tamoxifen&nbsp;16%,&nbsp;<em>P</em>&lt;0.001).&nbsp;In&nbsp;total&nbsp;45%&nbsp;of&nbsp;patients&nbsp;in&nbsp;the&nbsp;letrozole&nbsp;group&nbsp;versus35% of&nbsp;patients&nbsp;in&nbsp;the&nbsp;tamoxifen&nbsp;group&nbsp;(<em>P</em>=0.02)&nbsp;underwent&nbsp;breast-conserving&nbsp;therapy).&nbsp;During&nbsp;the&nbsp;4-month pre-operative&nbsp;treatment&nbsp;period,&nbsp;12% of patients&nbsp;treated&nbsp;with&nbsp;letrozole and 17% of patients&nbsp;treated with tamoxifen had disease progression on clinical assessment.</p><p>&nbsp;</p><p><u>First-line&nbsp;treatment</u></p><p>One controlled double-blind&nbsp;trial was conducted comparing&nbsp;letrozole 2.5 mg to tamoxifen 20 mg as first-line&nbsp;therapyin&nbsp;postmenopausal&nbsp;women&nbsp;with&nbsp;advanced&nbsp;breast&nbsp;cancer.&nbsp;In&nbsp;907&nbsp;women,&nbsp;letrozole&nbsp;was superior&nbsp;to&nbsp;tamoxifen&nbsp;in&nbsp;time&nbsp;toprogression&nbsp;(primary&nbsp;endpoint)&nbsp;and&nbsp;in&nbsp;overall objective&nbsp;response,&nbsp;time to treatment failure and clinical benefit.</p><p>&nbsp;</p><p>The&nbsp;results&nbsp;are&nbsp;summarised&nbsp;in&nbsp;Table&nbsp;9:</p><p><u><strong>Table&nbsp;9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Results&nbsp;at&nbsp;a&nbsp;median&nbsp;follow-up&nbsp;of&nbsp;32&nbsp;months</strong></u></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Variable</strong></p></td><td style="vertical-align:top"><p><strong>Statistic</strong></p></td><td style="vertical-align:top"><p><strong>Letrozole&nbsp;N=453</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen&nbsp;N=454</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Time&nbsp;to&nbsp;progression</strong></p></td><td style="vertical-align:top"><p>Median</p><p>(95%&nbsp;CI&nbsp;for&nbsp;median) Hazard ratio (HR) (95% CI for HR)</p><p><em>P</em></p></td><td style="vertical-align:top"><p>9.4&nbsp;months</p><p>(8.9,&nbsp;11.6&nbsp;months)</p></td><td style="vertical-align:top"><p>6.0&nbsp;months</p><p>(5.4,&nbsp;6.3&nbsp;months)</p><p>0.72</p><p>(0.62,&nbsp;0.83)</p><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Objectiveresponse rate (ORR)</strong></p></td><td style="vertical-align:top"><p>CR+PR</p><p><strong>&nbsp;</strong></p><p>(95%&nbsp;CI&nbsp;for&nbsp;rate)</p><p>Odds&nbsp;ratio</p><p>(95%&nbsp;CI&nbsp;for&nbsp;odds&nbsp;ratio)</p><p><em>P</em></p></td><td style="vertical-align:top"><p>145&nbsp;(32%)</p><p><strong>&nbsp;</strong></p><p>(28,&nbsp;36%)</p></td><td style="vertical-align:top"><p>95&nbsp;(21%)</p><p><strong>&nbsp;</strong></p><p>(17,&nbsp;25%)</p><p>1.78</p><p>(1.32,&nbsp;2.40)</p><p>0.0002</p></td></tr></tbody></table><p>&nbsp;</p><p>Time to progression was significantly&nbsp;longer, and response rate significantly&nbsp;higher for letrozole irrespective&nbsp;ofwhether&nbsp;adjuvant&nbsp;anti-oestrogen&nbsp;therapy&nbsp;had&nbsp;been&nbsp;given&nbsp;or&nbsp;not.&nbsp;Time&nbsp;to&nbsp;progression&nbsp;was significantly&nbsp;longer for letrozole irrespective of dominant site of disease. Median time to progression was 12.1 months for letrozole and 6.4 months for tamoxifen&nbsp;in patients with soft tissue disease only and&nbsp;median&nbsp;8.3&nbsp;months&nbsp;for&nbsp;letrozole&nbsp;and&nbsp;4.6&nbsp;months&nbsp;fortamoxifen&nbsp;in&nbsp;patients&nbsp;with&nbsp;visceral metastases.</p><p>&nbsp;</p><p>Study design allowed patients&nbsp;to cross over upon progression&nbsp;to the other therapy&nbsp;or discontinue&nbsp;from the&nbsp;study.Approximately&nbsp;50%&nbsp;of&nbsp;patients&nbsp;crossed&nbsp;over&nbsp;to&nbsp;the&nbsp;opposite&nbsp;treatment&nbsp;arm&nbsp;and&nbsp;crossover&nbsp;was virtually completed by 36 months. The median time to crossover was 17 months (letrozole to tamoxifen) and 13 months (tamoxifen to letrozole).</p><p>&nbsp;</p><p>Letrozole treatment in the first-line therapy of advanced breast cancer resulted in a median overall survival&nbsp;of&nbsp;34months&nbsp;compared&nbsp;with&nbsp;30&nbsp;months&nbsp;for&nbsp;tamoxifen&nbsp;(logrank&nbsp;test&nbsp;P=0.53,&nbsp;not&nbsp;significant). The absence&nbsp;of an advantagefor letrozole on overall survival could be explained&nbsp;by the crossover design of the study.</p><p>&nbsp;</p><p><u>Second-line&nbsp;treatment</u></p><p>Two&nbsp;well-controlled&nbsp;clinical&nbsp;trials&nbsp;were&nbsp;conducted&nbsp;comparing&nbsp;two&nbsp;letrozole&nbsp;doses&nbsp;(0.5&nbsp;mg&nbsp;and&nbsp;2.5&nbsp;mg) to&nbsp;megestrolacetate&nbsp;and&nbsp;to&nbsp;aminoglutethimide,&nbsp;respectively,&nbsp;in&nbsp;postmenopausal&nbsp;women&nbsp;with&nbsp;advanced breast cancer previously treated with anti-oestrogens.</p><p>Time to progression was not significantly&nbsp;different between letrozole 2.5 mg and megestrol&nbsp;acetate (<em>P</em>=0.07).Statistically&nbsp;significant&nbsp;differences&nbsp;were&nbsp;observed&nbsp;in&nbsp;favour&nbsp;of&nbsp;letrozole&nbsp;2.5 mg&nbsp;compared&nbsp;to megestrol&nbsp;acetate in overall&nbsp;objective&nbsp;tumour response&nbsp;rate (24% vs 16%,&nbsp;<em>P</em>=0.04),&nbsp;and in time to treatment&nbsp;failure&nbsp;(<em>P</em>=0.04).&nbsp;Overallsurvival&nbsp;was&nbsp;not&nbsp;significantly&nbsp;different&nbsp;between&nbsp;the&nbsp;2&nbsp;arms&nbsp;(<em>P</em>=0.2).</p><p>&nbsp;</p><p>In the second&nbsp;study, the response&nbsp;rate was not significantly&nbsp;different between&nbsp;letrozole 2.5 mg and aminoglutethimide&nbsp;(<em>P</em>=0.06).&nbsp;Letrozole&nbsp;2.5&nbsp;mg&nbsp;was&nbsp;statistically&nbsp;superior&nbsp;to&nbsp;aminoglutethimide&nbsp;for&nbsp;time to progression(<em>P</em>=0.008),&nbsp;time to treatment failure (<em>P</em>=0.003) and overall survival (<em>P</em>=0.002).</p><p>&nbsp;</p><p><u>Male&nbsp;breast&nbsp;cancer</u></p><p>Use&nbsp;of&nbsp;letrozole&nbsp;in&nbsp;men&nbsp;with&nbsp;breast&nbsp;cancer&nbsp;has&nbsp;not&nbsp;been&nbsp;studied.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Letrozole is rapidly and completely absorbed from the gastrointestinal tract (mean absolute bioavailability: 99.9%). Food slightly decreases the rate of absorption (median t<sub>max</sub>: 1 hour fasted versus&nbsp;2&nbsp;hours&nbsp;fed;&nbsp;and&nbsp;mean&nbsp;C<sub>max</sub>:&nbsp;129&nbsp;&plusmn;20.3&nbsp;nmol/litre&nbsp;fasted&nbsp;versus&nbsp;98.7&nbsp;&plusmn;&nbsp;18.6&nbsp;nmol/litre&nbsp;fed)&nbsp;but the extent of absorption (AUC) is not changed. The minor effect on the absorption rate is not considered to be of clinical relevance and therefore letrozole may be taken without regard to&nbsp;mealtimes.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Plasma protein binding of letrozole is approximately 60%, mainly to albumin (55%). The concentration&nbsp;of&nbsp;letrozolein&nbsp;erythrocytes&nbsp;is&nbsp;about&nbsp;80%&nbsp;of&nbsp;that&nbsp;in&nbsp;plasma.&nbsp;After&nbsp;administration&nbsp;of</p><p>2.5 mg&nbsp;<sup>14</sup>C-labelled letrozole, approximately 82% of the radioactivity in plasma was unchanged compound.Systemic&nbsp;exposure&nbsp;to&nbsp;metabolites&nbsp;is&nbsp;therefore&nbsp;low. Letrozole&nbsp;is&nbsp;rapidly&nbsp;and&nbsp;extensively distributed to tissues. Its apparent volume of distribution at steady state is about 1.87 &plusmn; 0.47 L/kg.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Metabolic clearance to a pharmacologically inactive carbinol metabolite is the major elimination pathway of letrozole (CL<sub>m</sub>= 2.1 L/h) but is relatively slow when compared to hepatic blood flow&nbsp;(about 90 L/h). The cytochrome P450 isoenzymes 3A4 and 2A6 were found to be capable of converting letrozole to this metabolite. Formation of minor unidentified metabolites and direct renal and&nbsp;faecal&nbsp;excretion&nbsp;play&nbsp;only&nbsp;a&nbsp;minor&nbsp;role&nbsp;in&nbsp;theoverall&nbsp;elimination&nbsp;of letrozole.&nbsp;Within&nbsp;2&nbsp;weeks&nbsp;after administration of 2.5 mg&nbsp;<sup>14</sup>C-labelled letrozole to healthy postmenopausal volunteers, 88.2 &plusmn; 7.6% of the radioactivity was recovered in urine and 3.8 &plusmn; 0.9% in faeces. At least 75% of the radioactivity recovered in urine up to 216 hours (84.7 &plusmn; 7.8% of the dose) was attributed to the glucuronide of the carbinol metabolite, about 9% to two unidentified metabolites, and 6% to unchanged letrozole.</p><p>&nbsp;</p><p>The&nbsp;apparent&nbsp;terminal&nbsp;elimination&nbsp;half-life&nbsp;in&nbsp;plasma&nbsp;is&nbsp;about&nbsp;2&nbsp;days.&nbsp;After&nbsp;daily&nbsp;administration&nbsp;of</p><p>2.5 mg steady-state levels are reached within 2 to 6 weeks. Plasma concentrations at steady state are approximately 7 times higher than concentrations measured after a single dose of 2.5 mg, while they are&nbsp;1.5&nbsp;to&nbsp;2&nbsp;times&nbsp;higher&nbsp;than&nbsp;thesteady-state&nbsp;values&nbsp;predicted&nbsp;from&nbsp;the&nbsp;concentrations&nbsp;measured&nbsp;after a single dose, indicating a slight non-linearity in the pharmacokinetics of letrozole upon daily administration of 2.5 mg. Since steady-state levels are maintained over time, it can be concluded that no continuous accumulation of letrozole occurs.</p><p><u>Special&nbsp;populations</u></p><p><em>Eldery</em></p><p>Age&nbsp;had&nbsp;no&nbsp;effect&nbsp;on&nbsp;the&nbsp;pharmacokinetics&nbsp;of&nbsp;letrozole.</p><p>&nbsp;</p><p><em>Renal&nbsp;impairment</em></p><p>In&nbsp;a&nbsp;study&nbsp;involving&nbsp;19&nbsp;volunteers&nbsp;with&nbsp;varying&nbsp;degrees&nbsp;of&nbsp;renal&nbsp;function&nbsp;(24-hour&nbsp;creatinine&nbsp;clearance 9-116 ml/min) no effect on the pharmacokinetics of letrozole was found after a single dose of 2.5 mg.</p><p>&nbsp;</p><p><em>Hepatic&nbsp;impairment</em></p><p>In a similar study involving subjects with varying degrees of hepatic function, the mean AUC values&nbsp;of the volunteers with moderate hepatic impairment (Child-Pugh B) was 37% higher than in normal subjects,&nbsp;but&nbsp;stillwithin&nbsp;the&nbsp;range&nbsp;seen&nbsp;in&nbsp;subjects&nbsp;without&nbsp;impaired&nbsp;function.&nbsp;In&nbsp;a&nbsp;study&nbsp;comparing&nbsp;the pharmacokinetics of letrozole after a single oral dose in eight male subjects with liver cirrhosis and severe hepatic impairment (Child-Pugh C) to those in healthy volunteers (N=8), AUC and t<sub>1/2</sub>&nbsp;increased by 95 and 187%, respectively. Thus letrozole should be administered with caution to&nbsp;patients with severe hepatic impairment and after consideration of the risk/benefit in the individual&nbsp;patient.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In&nbsp;a variety&nbsp;of&nbsp;preclinical&nbsp;safety&nbsp;studies&nbsp;conducted&nbsp;in&nbsp;standard&nbsp;animal&nbsp;species,&nbsp;there&nbsp;was&nbsp;no&nbsp;evidence of systemic or target organ toxicity.</p><p>&nbsp;</p><p>Letrozole&nbsp;showed&nbsp;a&nbsp;low&nbsp;degree&nbsp;of&nbsp;acute&nbsp;toxicity&nbsp;in&nbsp;rodents&nbsp;exposed&nbsp;up&nbsp;to&nbsp;2000 mg/kg. In&nbsp;dogs letrozole caused signs of moderate toxicity at 100 mg/kg.</p><p>&nbsp;</p><p>In repeated-dose toxicity&nbsp;studies&nbsp;in&nbsp;rats and dogs up&nbsp;to&nbsp;12 months, the main findings observed can be attributed&nbsp;tothe&nbsp;pharmacological&nbsp;action&nbsp;of&nbsp;the&nbsp;compound.&nbsp;The&nbsp;no-adverse-effect&nbsp;level&nbsp;was&nbsp;0.3&nbsp;mg/kg in both species.</p><p>&nbsp;</p><p>Both&nbsp;<em>in&nbsp;vitro&nbsp;</em>and&nbsp;<em>in&nbsp;vivo&nbsp;</em>investigations&nbsp;on&nbsp;letrozole&#39;s&nbsp;mutagenic&nbsp;potential&nbsp;revealed&nbsp;no&nbsp;indications&nbsp;of any genotoxicity.</p><p>&nbsp;</p><p>In&nbsp;a&nbsp;104-week&nbsp;rat&nbsp;carcinogenicity&nbsp;study,&nbsp;no&nbsp;treatment-related&nbsp;tumours&nbsp;were&nbsp;noted&nbsp;in&nbsp;male&nbsp;rats.&nbsp;In female rats, a reduced incidence of benign and malignant mammary tumours at all the doses of letrozole was found.</p><p>&nbsp;</p><p>Letrozole&nbsp;was&nbsp;embryotoxic&nbsp;and&nbsp;foetotoxic&nbsp;in&nbsp;pregnant&nbsp;rats&nbsp;and&nbsp;rabbits&nbsp;following&nbsp;oral&nbsp;administration&nbsp;at clinicallyrelevant&nbsp;doses. In rats that had&nbsp;live foetuses,&nbsp;there&nbsp;was an increase&nbsp;in the&nbsp;incidence&nbsp;of foetal malformations&nbsp;includingdomed&nbsp;head&nbsp;and&nbsp;cervical/centrum&nbsp;vertebral&nbsp;fusion.&nbsp;An&nbsp;increased&nbsp;incidence&nbsp;of foetal malformations&nbsp;was not seen in the rabbit. It is not known whether this was an indirect consequence of the pharmacological&nbsp;properties&nbsp;(inhibition of oestrogen biosynthesis)&nbsp;or a direct drug effect (see sections 4.3 and 4.6).</p><p>&nbsp;</p><p>Preclinical&nbsp;observations&nbsp;were&nbsp;confined&nbsp;to&nbsp;those&nbsp;associated&nbsp;with&nbsp;the&nbsp;recognised&nbsp;pharmacological&nbsp;action, which is the only safety concern for human use derived from animal studies.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Tablet&nbsp;core</em></strong></p><p>Lactose&nbsp;monohydrate</p><p>Maize starch</p><p>Sodium&nbsp;starch&nbsp;glycolate&nbsp;type&nbsp;A</p><p>Microcrystalline cellulose</p><p>Colloidal anhydrous silica</p><p>Magnesium stearate</p><p>&nbsp;</p><p><strong><em>Tablet coating&nbsp;</em></strong></p><p>Polyvinyl&nbsp;alcohol&nbsp;Talc</p><p>Macrogol 3350&nbsp;</p><p>Titanium&nbsp;dioxide&nbsp;(E171)</p><p>Iron&nbsp;oxide&nbsp;yellow&nbsp;(E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not&nbsp;applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                5 years

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium/PVC&nbsp;blisters.</p><p>Tablet&nbsp;containers&nbsp;(HDPE)&nbsp;closed&nbsp;with&nbsp;child&nbsp;resistant&nbsp;screw&nbsp;cap&nbsp;(HDPE/PP/LDPE&nbsp;or&nbsp;PP).</p><p>&nbsp;</p><p><em>Pack&nbsp;sizes:</em></p><p>Blisters:&nbsp;10,&nbsp;14,&nbsp;20,28,&nbsp;30,&nbsp;50,&nbsp;60,&nbsp;84,&nbsp;100,&nbsp;120&nbsp;film-coated&nbsp;tablets</p><p>Tablet&nbsp;containers:&nbsp;30,&nbsp;100&nbsp;film-coated&nbsp;tablets Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any&nbsp;unused&nbsp;medicinal&nbsp;product&nbsp;or&nbsp;waste&nbsp;material&nbsp;should&nbsp;be&nbsp;disposed&nbsp;of&nbsp;in&nbsp;accordance&nbsp;with&nbsp;local&nbsp;requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tadawi Biomedical company
Olaya st, 
Riyadh, 
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                XXXX
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>